

**Canadian Urological Association guideline: Management of ureteral calculi**

Jason Y. Lee, MD<sup>1</sup>; Sero Andonian, MD<sup>2</sup>; Naeem Bhojani, MD<sup>3</sup>; Jennifer Bjazevic, MD<sup>4</sup>; Ben H. Chew, MD<sup>5</sup>; Shubha De, MD<sup>6</sup>; Hazem Elmansy, MD<sup>7</sup>; Andrea G. Lantz-Powers, MD<sup>8</sup>; Kenneth T. Pace, MD<sup>1</sup>; Trevor D. Schuler, MD<sup>6</sup>; Rajiv K. Singal, MD<sup>1</sup>; Peter Wang, MD<sup>9</sup>; Michael Ordon, MD<sup>10</sup>

<sup>1</sup>Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; <sup>2</sup>Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada; <sup>3</sup>Department of Urology, Université de Montréal, Montreal, QC, Canada; <sup>4</sup>Division of Urology, Department of Surgery, Western University, London, ON, Canada; <sup>5</sup>Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; <sup>6</sup>Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada; <sup>7</sup>Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada; <sup>8</sup>Department of Urology, Dalhousie University, Halifax, NS, Canada; <sup>9</sup>London Health Sciences Centre, Western University, London, ON, Canada; <sup>10</sup>Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada

**Reviewer:** John Dushinski, MD

**Acknowledgement:** *The authors would like to thank Simon Czajkowski, MSc (Phys), MBE, for his assistance in collating and synthesizing the many references in this document. They also thank Robin Parker, MLIS, PhD(c), for her assistance in conducting the literature search for the section on SWL.*

**Cite as:** Lee JY, Andonian S, Bhojani N, et al. Canadian Urological Association guideline: Management of ureteral calculi. *Can Urol Assoc J* 2021 August 24; Epub ahead of print.  
<http://dx.doi.org/10.5489/cuaj.7581>

Published online August 21, 2021

**Corresponding author:** Dr. Jason Y. Lee, Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada; [jasonleeuoft@gmail.com](mailto:jasonleeuoft@gmail.com)

\*\*\*

**Introduction**

Globally, the prevalence of urolithiasis is steadily increasing, and though some regional variability exists, contemporary estimates report up to 10-12% of men and 7-8% of women now suffer from nephrolithiasis.<sup>1-3</sup>

Renal colic is one of the most frequent and expensive emergency department (ED) presentations.<sup>1,2</sup> A study comparing renal colic management patterns in 2 Canadian cities identified widely varying trends in care, with admission rates as high as 60%, and surgical intervention rates over 50%. Though early intervention has been purported to allow patients to return back to normal

life sooner, it appears early intervention led to increased subsequent ED visits, readmissions and secondary procedures.<sup>4</sup> Another study looking at costs associated with management of acute renal colic found that an initial trial of non-surgical management was associated with lower indirect costs.<sup>5</sup>

The aim of this CUA guideline document is to provide evidence-based consensus recommendations on various aspects relevant to the management of ureteral stones; the major topic areas included were conservative management, medical expulsive therapy, shockwave lithotripsy (SWL), ureteroscopy (URS) and special clinical scenarios (e.g. pregnancy, pediatrics).

## Methods

Separate reviews of the literature were performed for each of the major topic areas. English language publications were identified from Pubmed/Medline with a focus on recent publications since our last CUA guideline document on ureteral stones published in 2015.<sup>6</sup> The 2011 University of Oxford Centre for Evidence Based Medicine Levels of Evidence grading system was used to evaluate the level of evidence of recommendations included in the document.<sup>7</sup> All recommendations were based on expert review of the literature and represents the consensus of all authors of this guideline document.

### 1. Conservative management of ureteral stones

Non-operative management remains a reasonable first line approach for most patients presenting with ureteral stones. A 2010 meta-analysis of 37 studies demonstrated that 38-71% of symptomatic ureteral stones <4mm would pass spontaneously.<sup>8</sup> As well, looking at the placebo control arms of several large RCTs evaluating the efficacy of medical expulsive therapy (MET), spontaneous passage rates range from 40-80% for stones <10mm.<sup>9-11</sup> Clearly, an initial course of conservative management seems reasonable for many.

The urologist is often called upon in the setting of a suspected “septic stone” – conservative management is not an option in this setting. With a sufficient index of suspicion, early goal directed therapy including blood and urine cultures, broad-spectrum intravenous antibiotics, resuscitation and source control is paramount. Decompression of an obstructed pyelonephritis reduces mortality<sup>12</sup> and avoiding delays can prevent prolonged hospital admissions.<sup>13</sup> The method of drainage should be tailored to the patient’s clinical scenario, stone characteristics, as well as to the available resources at each centre.<sup>14,15</sup> In the only prospective randomized trial, patients presenting with a fever > 38°C, leukocytosis, and obstructing stone <15 mm were randomized to either a ureteric stent or a nephrostomy tube (NT).<sup>16</sup> There were no differences in any clinical outcome evaluated, including time-to-defervescence, duration of hospital stay, and resolution of obstruction. Other studies have also found that timely decompression is paramount, regardless of method.<sup>17-19</sup> It is generally agreed that definitive treatment should not be undertaken until the obstructed system has been decompressed and the infection adequately treated. Although, there is no strong evidence as to how long to wait after initial treatment, one study recommends a minimum of 7 days before definitive treatment.<sup>20</sup>

While patients with true urosepsis (life threatening organ dysfunction caused by a dysregulated response to a GU infection)<sup>21</sup> are more easily identified, accurately diagnosing pre-septic patients with a concomitant UTI and an obstructing stone may not be as clear. Irritative lower urinary tract symptoms, hematuria and pro-inflammatory urine/blood markers have led to inconsistent interpretation about the presence of infection and ultimately antibiotic utilization.<sup>22</sup> Many patients are inappropriately given antibiotics and there is an opportunity to improve clinical practice and antibiotic stewardship with some continued medical education initiatives.

Acute kidney injury (AKI) is present in approximately 6% of patients presenting with renal colic.<sup>23</sup> When significant renal impairment accompanies ureteral stones, early decompression or definitive therapy may mitigate further deterioration. Early intervention may also be indicated if the patient with a ureteral stone presents with intractable symptoms (pain, nausea, etc.) or significant frailty/comorbidities.

There is limited data supporting early surgical intervention rather than a period of initial conservative therapy, with one RCT demonstrating that early ureteroscopic management (<12hrs after ED admission) led to similar stone-free and complication rates but lower rates of post-op stenting.<sup>24</sup> Two RCTs looking at early SWL (<48hrs) vs. delayed SWL (2-7days) demonstrated earlier time to stone-free status, fewer required treatments and perhaps lower complications in the early SWL arms.<sup>25,26</sup> Importantly, these studies had a high risk of bias, highlighted by the fact that spontaneous stone passage rates in the delayed intervention arms of these RCTs was only 0-5.4%.

**Recommendation: Many patients with ureteral stones can initially be managed non-operatively, as spontaneous passage rates are high, particularly for smaller stones (<5 mm). Close follow-up is necessary for those being managed conservatively, to ensure spontaneous stone passage or to decide upon the need for timely intervention (level 2, strong recommendation). Obstructive pyelonephritis requires early goal-directed therapy including timely decompression in an antegrade or retrograde fashion, whichever method is most expedient (level 2, strong recommendation).**

### **Imaging**

Use of Computed-tomography (CT) scans have increased by over 10-fold in recent years,<sup>27</sup> being performed in 90% of those diagnosed with urolithiasis in the acute setting, whereas ultrasonography (US) is used in less than 7% of these patients.<sup>28</sup> There is evidence to suggest patient gender may impact initial imaging modality selected.<sup>29,30</sup> A large, randomized trial comparing initial imaging modalities for renal colic presentations in the ED found most clinical outcomes were equivalent between US and non-contrast CT (NCCT) imaging, recommending initial US given the lack of radiation exposure (28). In this RCT, USs performed by radiologists, compared to point-of-care US (POCUS) were less likely to result in follow-up CT scans, but did increase visit times within the ED.<sup>31</sup> While POCUS is convenient, it is more operator-dependent and consulting teams often have no images or formal report to review. Details found on a NCCT are often, but not always, required for definitive stone management and follow-up, particular for complex scenarios.

Supplementing US with Kidney-Ureter-Bladder (KUB) x-rays can enhance the sensitivity of detecting a ureteral stone. Studies demonstrate that combining these modalities results in sensitivity ranging from 79-100%, and specificity up to 100%.<sup>32</sup> One study also demonstrated that the addition of a formal KUB x-ray, even when CT scout images were available, improved follow-up diagnostic accuracy.<sup>33</sup> Obtaining a KUB x-ray at the time of a diagnostic imaging in the ED is useful for not only determining stone composition, but also to track the progress of stone passage in follow-up.

Reduced dose NCCT scans have been shown to maintain sensitivities and specificities between 90-97%, while preserving enough detail to identify alternate diagnoses. When assessing for stones specifically, body-mass index (BMI) has been shown to be less of a concern with >95% diagnostic accuracy and radiation doses <3.7mGy regardless of BMI.<sup>34</sup> Though dual energy CT scans have shown utility in identifying uric acid stone composition,<sup>35</sup> there is little additional benefit in the acute setting as obstructing stones are not typically treated with dissolution therapy.

Overall, while adhering to as-low-as-reasonably-achievable (ALARA) radiation exposure principles, the patient's age, pregnancy status, stone history and preceding exposure to ionizing radiation should be considered whenever ordering imaging for non-life-threatening indications. An over-reliance on CT imaging has been identified and should be addressed in our practice patterns.

**Recommendation: Ultrasonography with KUB x-ray should be considered the initial modality of choice for acute ureteral stones. Judicious use of CT scans, preferably low-dose, provides valuable information for management decisions (level 1, strong recommendation). While often omitted, the utility of a KUB x-ray at the time of presentation is very important for future follow-up and decision-making regarding definitive treatment options (level 4, expert opinion).**

### *Discharge planning*

#### *Medical expulsive therapy (MET)*

Recently, several large RCTs<sup>11,36,37</sup> failed to show improved stone passage or reduce analgesic requirements when using alpha-blockers for MET. However, several published meta-analyses<sup>38-40</sup> suggest overall benefit of MET for ureteral stones. Subgroup analysis data suggests this benefit may be mainly for larger stones (5-10mm) in the distal ureteral stones.<sup>36,37,40-42</sup> A Cochrane review of 67 studies analyzed all studies, specifically looking at lower and higher quality studies. The higher quality, placebo-controlled studies showed a benefit with MET (RR 1.16, 95% CI 1.07 to 1.25) and a decrease in hospitalizations (RR 0.51, 95% CI 0.34 to 0.77) and no significant changes in the need for intervention.<sup>43</sup>

#### *Analgesia*

Moving away from a reliance on opioids in acute care patients with renal colic is important and these patients have been found to do well with non-opiate analgesia.<sup>44</sup> In one study, 1500 adult acute care patients were randomized to intramuscular diclofenac, intravenous morphine or intravenous paracetamol. At 30 minutes non-steroidal anti-inflammatories (NSAIDs) were more effective in reducing pain by 50% compared to morphine, with no adverse events.<sup>45</sup> Another

randomized trial showed protocolled non-opioid analgesia could reduce opioid requirements during initial presentation if first- and second-line interventions included NSAIDs and intravenous lidocaine. However, opioid-sparing approaches were associated with higher rates of repeat visits to the ED.<sup>46</sup> Discharge prescriptions can vary significantly based on the patient population and comorbidities. Accounting for important patient characteristics (e.g. post-traumatic stress disorder, anxiety/depression, chronic pain syndromes) when prescribing analgesia for acute renal colic is also important.<sup>47,48</sup>

#### *Forced hydration*

While there is clear utility in re-hydrating hypovolemic patients with significant nausea and vomiting, or in those with a suspected pre-renal AKI, intravenous hydration for the sole purpose of forced stone passage is not supported by the literature and should be avoided.<sup>49</sup>

**Recommendation: The role of MET in promoting spontaneous passage is controversial, but the current literature suggests if there is any benefit, it is for larger (5-10 mm) ureteral (distal) stones. The advantages and disadvantages of MET should be discussed with the patient in a shared decision-making process (level 1, strong recommendation). The use of opioid-sparing analgesic regimens have been shown to be efficacious and opioids for management of renal colic should be minimized; patient education is paramount (level 1, strong recommendation). Forced intravenous (IV) hydration for the purposes of stone expulsion is not recommended (level 1, moderate recommendation).**

#### *Renal colic followup*

Unfortunately, neither resolution of symptoms nor patient reports of successful passage of obstructing ureteral stones is always confirmatory. One study demonstrated that 6.2% of patients reporting passage of a symptomatic ureteral stone had persistent obstruction on follow-up CT scan imaging.<sup>50</sup> Another study demonstrated that resolution of pain was only 79.7% sensitive and 55.8% specific for successful passage of a ureteral stone, based on follow-up US and KUB x-ray imaging.<sup>51</sup> As such, follow-up imaging to ensure passage of an obstructing ureteral stone is suggested. The ideal imaging modality of choice remains uncertain, but one study found that 38% of patients with a persistent ureteral stone, confirmed on ultra-low dose CT, had neither hydronephrosis on CT nor a visible stone on the CT scout image.<sup>52</sup>

Data suggests the majority of patients that will pass ureteral stones spontaneously, will do so within approximately one month of presentation<sup>11, 33-34</sup>. Examining the literature on long-term renal damage and ureteral obstruction, it is difficult to elucidate an objectively safe or unsafe duration of observation for a ureteral stone where no imperative indication for treatment exists; the data is mainly from animal studies and usually involves a complete obstruction model. While degree and duration of obstruction are clearly important, other factors unique to each patient also need to be considered; poor baseline renal function, older age, male gender, presence of certain comorbidities (eg diabetes) have been associated with increased risk of chronic kidney disease.<sup>53,54</sup>

**Recommendation: Resolution of symptoms and patient-reported stone passage after a bout of renal colic do not always confirm passage of an obstructing ureteral stone. Follow-up imaging is recommended to confirm stone passage (level 3, strong recommendation). The recommended duration of conservative management is unique to each patient, with multiple factors to be considered. Surgical intervention should likely be considered if a patient has not passed an obstructing ureteral stone after 4-6 weeks (level 5, moderate recommendation).**

## 2. Shockwave lithotripsy

Despite the advances in ureteroscopes and laser technologies, SWL remains a first-line treatment option for ureteral calculi. SWL outcomes can be directly influenced by case selection, surgeon technique, and modifiable parameters to enhance safety and maximize successful outcomes. Much of the data for SWL outcomes is derived from patients with renal calculi, but these findings should be generalizable to ureteric stones, particularly for those in the upper ureter, where renal parenchyma is included in the shockwave path.

### *Clinical factors affecting SWL treatment success*

#### *Composition*

The majority of stones are composed of calcium oxalate and most will fragment well with SWL treatment. There are certain stone compositions, such as cystine, pure calcium oxalate monohydrate and brushite that are more resistant to SWL and may be better served by ureteroscopic management.<sup>55</sup> Uric acid stones, while fragile in the face of SWL, require either the use of ultrasound or pyelography (intravenous or retrograde) for targeting during SWL.

#### *Stone density*

Stone density, as measured on NCCT scan in Hounsfield units (HU), has been shown to predict successful SWL outcomes. A crude surrogate for composition, a linear relationship exists between increased stone density and poor stone fragmentation with a threshold of 1000 HU, above which stones are less likely to be successfully fragmented.<sup>56-60</sup> The variation coefficient of stone density (VCSD), which is a measurement of stone heterogeneity on CT scan and reflects the crystal architecture of the stone, has been reported as a novel predictor of SWL success and may outperform HU as a predictor of success; however, further study in this measurement would be useful.<sup>61</sup>

#### *Skin-to-stone distance (SSD)*

A longer SSD has been associated with reduced treatment success for SWL for renal<sup>62-67</sup> and ureteral stones<sup>65</sup> with SSD greater than 10cm often associated with decreased stone-free rates (SFRs).

**Recommendation: Stone location, composition, density and skin-to-stone distance can help counsel patients regarding the success rates of SWL treatment. Known uric acid, cystine and brushite stones are likely best treated with URS (level 4, moderate recommendation). Patients**

**with ureteral stones with a density >1000 HU or SSD >10 cm have lower stone-free rates with SWL (level 2, strong recommendation) and shared decision-making with patients is important to balance the availability, morbidity and efficacy of SWL vs. URS.**

### *Optimizing treatment outcomes*

#### *Dose escalation/pause*

Gradually increasing SWL energy up to optimal dose allows for better patient accommodation to the sensation of treatment and, for upper ureteral stones, reduces renal injury by inducing renal vasoconstriction.<sup>68-72</sup> An alternative strategy is to pre-treat with a series of low energy shocks, then pause treatment for a short period of time before resuming at higher energy levels.<sup>68</sup>

#### *Number of treatments*

If SWL is not successful, it can be repeated, but the incremental benefit of more than two treatments for the same ureteric stone is small.<sup>73,74</sup> The optimal time interval between SWL treatments is unclear but can be short (2-3 days) for mid and distal ureteral stones.

#### *Treatment rate*

A number of randomized trials have indicated that a lower shock rate can improve stone fragmentation, particularly for stones larger than 1 cm. The optimal treatment rate is not clear, however, studies suggest that SWL at 60 to 90 shocks/min leads to better fragmentation than 120 shocks/min, particularly for larger stones.<sup>75-83</sup> Most studies were performed with renal calculi, however, improved outcomes have been demonstrated for upper ureteric stones as well.<sup>76</sup>

#### *Number of shocks*

The optimal number of shocks has not been definitively established but requires balancing treatment efficacy with adverse effects, particularly renal damage. For upper ureteral stones, the recommended shock rate range is 2000 to 3500, but manufacturer's guidelines should be closely considered.<sup>74</sup> For mid to distal ureteric stones, where the renal parenchyma is not affected by SWL energy, treatment can safely be carried out up to 4000 or more shocks.<sup>74</sup> Some studies have assessed the efficacy and safety of increasing the number of shock waves per session to >4000.<sup>84,85</sup>

**Recommendation: Patients with upper ureteric stones should initially receive low-energy shocks, with gradual voltage escalation up to maximum energy (level 2, strong recommendation). If unsuccessful, repeat SWL can be considered but more than two treatments to the same ureteric stone has little incremental benefit and URS should then be considered (level 4, moderate recommendation). Patients with upper ureteric stones >1cm or those selected for retreatment after initial failed SWL, should be treated at a rate <120 shocks/min for optimal fragmentation (level 1, strong recommendation). An adequate number of shocks (2000-4000 for most lithotripters) should be administered to ensure adequate treatment of ureteric stones (level 4, weak recommendation). A higher number of shocks may**

**result in improved SFRs, but data is limited to make this a recommendation for routine practice.**

DRAFT

*Alpha-blockers*

Alpha-blockers (most commonly tamsulosin) have been studied to assess their impact on SWL outcomes in multiple RCTs and meta-analyses.<sup>86,87,96,88–95</sup> Meta-analyses have shown improved SWL success rates,<sup>89,94–96</sup> time to stone passage, risk of steinstrasse,<sup>93–96</sup> and need for auxiliary procedures.<sup>93</sup> A Cochrane systematic review is underway assessing the use of alpha-blockers after SWL for renal or ureteral stones in adults but at the time of this guideline's publication the results were not yet available.<sup>97</sup> Additional benefits with respect to pain and analgesic use are also of interest.

*Stenting*

Routine pre-SWL stenting is not necessary and does not improve the success rate or passage of fragments.<sup>98–101</sup> In fact, having a stent may impede the passage of fragments following SWL and does not appear to decrease the risk of steinstrasse or infection,<sup>100–104</sup> with the possible exception of steinstrasse risk for stones >2cm.<sup>100</sup> Stents may be beneficial for obstructing stones, if relief of obstruction is warranted prior to treatment (e.g. obstruction with infection, renal failure, intolerable pain), and prior to SWL for stones in a solitary kidney.<sup>105</sup>

**Recommendation: Alpha blockers (e.g., tamsulosin) should be prescribed after SWL for ureteral stones to improve treatment success rates (level 1, moderate recommendation).**

**Ureteral stents do not improve SFRs after SWL and do not reduce the risk of steinstrasse or infection following SWL for most patients (i.e., stones <2 cm) (level 1, moderate recommendation).**

**3. Ureteroscopy**

Modern ureteroscopy (URS) is a mainstay in the surgical treatment of ureteral stones worldwide. As a result of advancements in technology in recent decades, URS can be safely performed with high SFR and relatively low complications.

*Preoperative alpha-blockers*

The use of alpha-blockers prior to URS appears to improve intraoperative outcomes and patient SFR. A recent systematic review and meta-analysis comprising of 12 RCTs and 1,352 patients evaluated alpha-blocker use before planned URS for the management of ureteral calculi.<sup>106</sup> With a median preoperative use of one week, a 61% risk reduction in need for ureteral dilatation was observed. Furthermore, the use of preoperative alpha-blockers significantly improved SFR (RR: 1.18, 95% CI: 1.11–1.24,  $p < 0.00001$ ), reduced operative time by an average of 6 minutes ( $p = 0.004$ ), and decreased patient hospital stay ( $p = 0.001$ ). Whether one week of use is optimal or simply convenient for patients was not defined. Larger, more appropriately powered RCTs may provide further direction regarding the efficacy of preoperative alpha-blockers for URS of ureteral stones.

**Recommendation: Preoperative alpha-blockers may improve intra-operative and post-operative outcomes for patients undergoing URS. However, the optimal duration of preoperative alpha-blocker therapy is still uncertain (*level 1, moderate recommendation*).**

### *Postoperative imaging*

The goal of postoperative imaging is to assess for residual stone burden and screen for ongoing obstruction. Residual stone fragments may lead to additional stone-related episodes and surgical intervention.<sup>107,108</sup> Some authors have concluded that in the setting of uncomplicated URS, routine postoperative upper tract imaging is not necessary.<sup>109</sup> Instead, they have recommended postoperative imaging indications include chronic stone impaction, significant ureteral trauma, prior renal impairment, endoscopic evidence of stricture, and postoperative pain or fever. However, silent obstruction, described as asymptomatic, persistent postoperative obstructive hydronephrosis, has been shown to occur at a rate of 1.9-10% following URS, highlighting the importance of routine postoperative imaging.<sup>109-111</sup> The mean interval from URS to possible development of ureteral stricture is estimated to be 13 months.<sup>112</sup> While NCCT is the best modality for identifying both residual fragments and postoperative obstruction, the effective dosage of radiation and the cost of this modality have prevented its routine use post-URS. Rather, a combination of US and KUB X-ray are typically used to detect obstruction and stone-free status.

**Recommendation: An US ± KUB X-ray is recommended following URS for ureteral stones. (*level 4, strong recommendation*). In complicated cases, further imaging with NCCT can be performed.**

### *Ureteral access sheaths*

Ureteral access sheaths (UAS) can offer numerous advantages during URS. They allow for rapid and multiple re-entries into the upper tract, potentially reducing damage to the ureteroscope. UAS can also enhance visibility, decrease intrarenal pressure, and allow for drainage and elimination of dust and stone fragments.<sup>113</sup> The proper selection of UAS size is crucial to balancing URS outcomes. Excessive force should never be applied when using UAS. Most of the literature on UAS use during URS is related to renal stones.

In a prospective cohort analysis of 2,239 patients, no significant difference in SFR was seen whether a UAS was or was not used during flexible URS (75.3% vs. 50.4%,  $p = 0.604$ ).<sup>114</sup> However, in subgroup analysis of stones  $\geq 10$ mm, SFRs were significantly higher in the UAS group (84.9% vs. 81.5%,  $p < 0.01$ ). One systematic review revealed no significant difference in operative times, SFRs, or intraoperative complications with UAS use.<sup>115</sup> A critical drawback of these systematic reviews is that a substantial number of studies did not use NCCT to determine true SFR and as a result, the impact of UAS use on SFR after URS remains unclear.

In a study of 2239 patients treated with flexible URS, no significant difference in ureteral injuries was reported in patients treated with UAS in comparison to those without UAS.<sup>114</sup> Grades of ureteral injuries related to UAS were reported as low-grade injuries involving the mucosa in

almost half of patients and high-grade lesions involved smooth muscle layer in 15% of patients.<sup>116</sup> Importantly, endoscopically detected high-grade ureteral lesions following UAS insertion do not appear to result in an increased rate of stricture.<sup>117</sup>

**Recommendation: Current evidence suggests UAS use for ureteral stones has no significant impact on SFR nor on intraoperative complications (level 2, moderate recommendation), but may improve visualization, reduce intra-renal pressures, and facilitate fragment removal (level 4, strong recommendation).**

### **Stenting**

Ureteral stent placement prior to elective URS can facilitate UAS and ureteroscopy insertion. In a recent prospective study of rigid and flexible ureteroscopes, the ureter was inaccessible in 8% of cases, necessitating the placement of a ureteral stent and delayed definitive treatment.<sup>118</sup> Some studies have demonstrated no clear advantage in SFR nor complication rate with routine pre-op stenting<sup>119,120</sup> while others have shown routine pre-URS stenting was associated with a higher SFR for larger stones.<sup>121–123</sup>

The impact of post-URS stenting on SFR is not clear and meta-analyses have shown conflicting results. One recent meta-analysis found that stenting did not improve SFR nor reduce late postoperative complications after routine URS.<sup>124</sup> Conversely, in another meta-analysis of 22 RCTs, the SFR was significantly better in the stented group (95% CI: 0.34 to 0.89;  $p = 0.01$ ).<sup>101</sup> In terms of the impact on stricture rate, a meta-analysis of 14 trials and 1,652 patients demonstrated that post-URS stenting likely does not reduce stricture rates at 90 days (RR 0.58, CI 0.23 to 1.47).<sup>125</sup> Conversely, use of a stent has been shown to reduce unplanned medical visits post-URS.<sup>125–127</sup> Following UAS use, routine ureteral stenting seems to be beneficial in reducing pain and unplanned medical visits.<sup>128,129</sup>

Nonetheless, there are scenarios where routine post-URS stent placement is advisable; suspected ureteric injury or stricture, solitary kidney, and patient with renal impairment.

The evidence is not clear on whether use of a stent post-URS impacts opioid use,<sup>125,130</sup> but urinary symptoms have been demonstrated to be significantly worse with stent use.<sup>101,124,126,131</sup> Studies have demonstrated beneficial effects of various medications (e.g. alpha-blockers, anticholinergics, B-agonists) to ameliorate stent-related urinary symptoms.<sup>132,133</sup>

There is no consensus regarding the optimum duration of postoperative stenting. In an animal model, there were no histological ischemic changes in the ureteral wall 72 hours post-UAS insertion suggesting that three days may be sufficient.<sup>134</sup> On the other hand, Paul et al. compared ureteral stent dwell times of 3 to 7 days and found that removal at 3 days was linked to a higher probability of obstruction-related adverse events (23% vs. 3%).<sup>135</sup>

**Recommendation: Routine pre-URS stenting is not necessary but may facilitate UAS insertion and improve SFRs in patients with larger stones (level 2, weak recommendation). Routine stenting after uncomplicated URS is likely unnecessary (level 2, strong recommendation) but**

**stent placement after UAS use is warranted (level 3, weak recommendation). Stent-related symptoms following URS may be ameliorated with alpha-blocker and/or anticholinergic medications (level 2, moderate recommendation). If access to the ureteral stone is complicated or impossible, placement of a stent and repeat URS is the safest option (level 5, strong recommendation).**

#### 4. Comparing treatment outcomes – SWL vs. URS

##### *Stone-free rate*

Previously published literature comparing SWL vs. URS for ureteric calculi, which focused largely on efficacy and safety, guided the development of the 2015 CUA guideline recommendations. Since then several other studies have been published, including some important data on cost-effectiveness and patient-reported outcomes. Due to the significant variation and heterogeneity the techniques used to perform SWL and URS, it is difficult to make clear recommendations based on published literature.

For upper ureteric stones, a randomized trial of semirigid URS compared to SWL for stones <2 cm showed similar SFR (86.6% vs. 82.2%) at 3 months.<sup>136</sup> Those undergoing SWL had significantly higher re-treatment rates but after re-treatment, the need for subsequent auxiliary treatments was similar (21.1% vs. 17.7%,  $p < 0.5$ ). When the groups were sub-stratified by stone size, URS produced a higher SFR for stones 1-2cm (85.4% vs. 78.4%), though this was not statistically significant. Complication rates were also statistically similar (11.1% vs. 6.6%,  $p = 0.21$ ).

When dealing with distal ureteral stones, URS has traditionally been thought to produce superior results to SWL. However, several studies have demonstrated similar SFR between SWL and URS, with the caveat that SWL often required more than one treatment to achieve that same SFR.<sup>137-140</sup> A systematic review published in 2017 found that there was a better SFR with URS at 4 weeks, but this was comparable between groups at 3 months.<sup>141</sup> There were fewer retreatments with URS, but higher complication rates. In terms of radiation doses to patients, one study showed equal amounts of radiation used for ureteral stones whether treating with URS or SWL.<sup>142</sup>

Costs can vary from region to region for each modality; an American study found that for ureteral stones  $\leq 1.5$  cm, the equivalency point for cost efficacy was when the SFR for SWL was <60-64% or if the chance of URS success was >57-76%.<sup>143</sup> For these situations, URS was found to be more cost effective in an American system. A British cost-efficacy study was undertaken according to their National Institute for Health and Care Excellence (NICE) guidelines<sup>144</sup> and they concluded that for ureteral stones <1cm, URS would be more costly even if SWL was only 40% efficacious.

**Recommendation: SWL produces similar SFR to URS for ureteral stones, albeit with a higher retreatment rate and lower complication rate (level 1, strong recommendation). While local/regional cost models need to be considered, SWL may be a more cost-effective option for ureteric stones (level 4, weak recommendation).**

### ***Patient-reported outcomes***

Ureteral stones can have a significant impact on the health-related quality of life (HRQOL) of patients.<sup>145-149</sup> Both SWL and URS have been found to have significant impacts on kidney stones patient's quality of life.

Overall, patients with ureteral stones are satisfied with their treatment choice approximately 50% of the time and there is no difference in treatment satisfaction correlated to the selected modality (SWL vs. URS).<sup>150-152</sup> However, in one study examining specifically distal ureteric calculi it was determined that more patients were satisfied with URS (n=113; 94.2%) compared to SWL (n=74; 80.4%) (p=0.002).<sup>153</sup>

Regarding HRQOL, the main HRQOL outcomes affected by SWL and URS are the physical functioning, social functioning and pain domains on the 36-item Short Form Health Survey (SF-36).<sup>154,155</sup> A study comparing the HRQOL between patients who received SWL to those who received URS using the SF-36, found that patients who received URS scored worse than those who received SWL due in part to the higher analgesic requirements and longer hospital stay after URS compared to SWL, which was mainly attributed to the use of a ureteral stent.<sup>156</sup> Interestingly, the improved HRQOL for SWL over URS extended beyond the short term and persisted at 6 months of follow-up despite the higher SFR with URS. In contrast, a study compared the impact of URS vs. SWL on the HRQOL of patients with proximal ureteral stones and found that although there was no difference in change in HRQOL for patients with stones <10mm, patients who underwent SWL for proximal ureteral stones >10mm scored significantly lower on their SF-36.<sup>157</sup> Finally, a systematic review examined how ureteric calculi influence HRQOL and patient treatment preference.<sup>158</sup> A number of studies were reviewed, however, overall URS and SWL were both found to significantly impact SF-36 results similarly.

**Recommendation: Overall, there is similar patient satisfaction between SWL and URS for the treatment of ureteric calculi, but SWL has been found to have slightly better HRQOL outcomes, due primarily to the avoidance of a ureteral stent (level 2, moderate recommendation).**

## **5. Special clinical considerations**

### ***Anti-coagulation***

Some studies have shown up to a 20- to 40-fold increased risk of peri-renal hematomas and haemorrhagic complications among patients with uncorrected coagulopathies undergoing SWL when compared with patients with a normal bleeding profile,<sup>159-162</sup> and so in consultation with a haematologist or a cardiologist, bleeding coagulopathies need to be corrected and anticoagulation therapy appropriately withheld around the time of SWL.<sup>163</sup> Patients with an increased risk of thromboembolic disease should be managed by bridging therapy while oral anticoagulation is held.<sup>164</sup>

A retrospective study of 434 patients on acetylsalicylic acid (ASA) or low-molecular-weight heparin (LMWH) undergoing SWL for renal and proximal ureteric stones demonstrated

that the continued use of ASA and a therapeutic, but not prophylactic, dose of LMWH were independent predictors of renal hematoma, as determined by ultrasound one day post-SWL.<sup>165</sup> A systematic review performed in 2014 found sparse and poor-quality evidence with respect to the safety of SWL while on antiplatelet or anticoagulant medications, but one of the authors' conclusions included careful consideration of SWL among patients on low-dose ASA.<sup>166</sup>

Recent advances in URS technology have made it possible for patients with coagulopathies to safely undergo URS and laser lithotripsy while anticoagulated.<sup>160,167–170</sup> However, this is associated with lower SFRs and increased risk of postoperative gross hematuria necessitating admission and bladder irrigation.<sup>161,171</sup> Therefore, risks and benefits of withholding anti-coagulation or proceeding with URS while anti-coagulated should be discussed with the patient and his/her cardiologist or haematologist.

In terms of using a UAS during URS for patients on anticoagulants, studies have demonstrated no increased risk of haemorrhagic complications.<sup>116,169</sup>

**Recommendations: SWL and antegrade URS are contraindicated in patients with uncorrected coagulopathies. When the risk of holding antiplatelet or anti-coagulants outweigh the benefits, proceeding with URS while a patient is anti-coagulated, is an acceptable option (level 2, moderate recommendation).**

#### *Antegrade management of ureteral stones*

Antegrade URS can be considered a treatment option in the following situations: (1) patients with a urinary diversion in whom SWL or retrograde access is not feasible; (2) in select cases with a large, impacted proximal ureteral stones; (3) when performed in conjunction with renal stone removal; (4) in select cases following failure of a retrograde URS attempt for a large, impacted proximal ureteral stone;<sup>172</sup> and (5) when the ureteral stone is in a transplant kidney.<sup>173</sup>

Dealing with stones in patients with urinary diversions represent a challenge to most urologists. The established anatomical changes in these patients necessitate accurate preoperative assessment by NCCT.<sup>174</sup> If SWL is not an option, or the patient's stone doesn't respond to SWL, one of the most important factors to consider is whether retrograde access to the ureter is possible. If the ureter is accessible through a retrograde approach (e.g. through an ileal conduit), flexible retrograde URS may be a good option as antegrade URS in these patients is associated with higher rates of postoperative fever or sepsis (8% vs. 0%,  $p < 0.05$ ) and higher rates of second-look nephroscopy (36% vs. 16%,  $p < 0.05$ ) compared to those with normal anatomy.<sup>175</sup>

For large (>15 mm), impacted proximal ureteral stones, the SFR with antegrade URS ranges between 98.5% and 100% with a low risk for complications.<sup>172,176–180</sup> However, as would be expected the antegrade approach is associated with longer fluoroscopy time, longer procedural time and longer hospital stay.<sup>181</sup>

**Recommendations: Percutaneous antegrade URS should be considered in the treatment of stones in patients with urinary diversion and select large, impacted proximal ureteral stones, especially when prior retrograde URS has failed (level 4, strong recommendation).**

### *Ureteral stones in children*

Paediatric urolithiasis has become increasingly common in the last two decades with the incidence increasing approximately 4-10% annually.<sup>182,183</sup>

### *Diagnostic imaging*

Due to concerns regarding radiation exposure in children, ultrasonography is used more commonly than in adults, as the first-line diagnostic modality when renal colic is suspected.<sup>184-186</sup> However, similar to adults, there are sensitivity issues with US; in particular for mid-ureteral calculi.<sup>187</sup> The addition of conventional radiography (KUB x-ray) can improve diagnostic accuracy,<sup>188,189</sup> but as in adults, NCCT has the highest sensitivity and specificity.<sup>185,186,190</sup> The use of ultra-low dose NCCT can mitigate radiation exposure to levels similar to KUB x-ray, while maintaining diagnostic performance.<sup>191,192</sup>

### *Management*

The optimal management of ureteral stones in children is dependent on patient and stone factors, similar to adults, but the anatomic spectrum of paediatric patients, and the subsequent management, varies much more widely.<sup>193</sup> Unless there is an indication to intervene acutely, a trial of passage of at least 2 weeks is first line management in children with urolithiasis <5 mm.<sup>105,185,193-196</sup> If urinary drainage is urgently required, ureteral stent insertion is preferred in children due to decreased complications compared to percutaneous decompression. Evidence suggests MET in children may be effective and safe.<sup>193,194,197</sup>

There is a paucity of high-level evidence in the literature regarding the optimal management algorithm for paediatric patients requiring surgical intervention for ureteric stones.<sup>193,198</sup> In children with mid to distal urolithiasis, URS has been consistently shown to be superior to SWL and thus is recommended as first line management.<sup>105,185,199-201</sup>

For children with proximal ureteral stones, the overall SFR between SWL and URS have been shown to be similar<sup>198</sup>, so both SWL and URS may be considered first-line options. The usual considerations regarding the suitability of SWL must be taken into account. In children with large stone burdens, repeated procedures may be required or discussions involving more invasive options (percutaneous antegrade URS or open/laparoscopic/robotic procedures) may be undertaken.<sup>105,185</sup>

Retrograde access for children who have undergone a Cohen cross-trigonal ureteral re-implantation can be uniquely challenging but is not a contraindication for URS.<sup>202</sup>

### *Complications*

The complication and re-treatment rates for paediatric SWL are similar to those of adults.<sup>198,199</sup> However, unlike the adult population, the complication rates for paediatric URS varies widely (3.7-20.5%).<sup>188,198,203,204</sup> In particular, overall reported rates of ureteral injury (2.1-2.8%), ureteric

stricture (0.2 – 1.0%) and ureteral avulsion (0.4%) are higher among the paediatric population.<sup>200,203</sup> The complications associated with paediatric URS are more strongly linked with age/size of the child and equipment size.<sup>203,205</sup> In order to minimize ureteric complications, it is recommended that ureteroscopes < 8 French be used on paediatric patients,<sup>199,200,204,205</sup> and that mini 4.5 French ureteroscopes be used for children < 3 years old.<sup>203</sup>

### *Stenting*

Data does not support routine pre-stenting prior to URS in children.<sup>105</sup> However, failed retrograde access is more common in children (30-70%) than adults.<sup>196,206</sup> In these situations, pre-stenting and repeat URS after passive dilation may be preferable to active dilation with catheters, balloon dilators and sheaths due to risk of significant ureteric trauma. This is especially true in younger children.<sup>188</sup>

Postoperative stenting should be performed at the discretion of the attending physician, with similar indications as in adults.<sup>185,205</sup>

### *Followup*

There are no clear differences between pediatric and adult follow-up post-surgical intervention for urolithiasis. In most series, postoperative ureteral stents are removed within 1-2 weeks under a second general anaesthesia. Alternative options include magnetic and tethered stents.

Postoperatively, children should be followed with an US and KUB x-ray 4-6 weeks after the procedure.<sup>200,205,207,208</sup> After their first episode of urolithiasis, the overall recurrence rates in the paediatric population ranges between 19 – 50 % over a follow-up of 2 to 3 years.<sup>195,209,210</sup> However, there is currently no high-level evidence dictating a specific surveillance schedule. As such, it is recommended that this mirror that of the adult population.

**Recommendation: Ultrasound is the first-line diagnostic modality used in children with suspected ureteral stones. This may be coupled with a KUB X-ray to increase accuracy. Low-dose NCCT may be used in certain situations (level 3, strong recommendation). A trial of passage with/without MET is recommended for children with smaller (<5mm) stones (level 2, strong recommendation). SWL is a safe and effective option for ureteral stones in children (level 2, strong recommendation). If ureteral dilation is required, passive dilation is preferred (level 4, moderate recommendation). It is recommended that ureteroscopes <8 French be used for URS in children (level 4, moderate recommendation).**

### *Pregnancy*

No Level 1 evidence exists regarding the treatment of ureteral stones during pregnancy. Retrospective case series provide some guidance on how to manage this situation.

### *Diagnostic imaging*

The first diagnostic test in suspected nephrolithiasis during pregnancy should be US (abdominal +/- transvaginal) due to the lack of radiation. However, if US is non-diagnostic, magnetic resonance

imaging (MRI) can be considered in the first trimester.<sup>211,212</sup> If available, a protocol involving magnetic resonance urography (MRU) with a T2-weighted half Fourier single-shot turbo spin-echo (HASTE) is preferred due to improved accuracy.<sup>213</sup> Ultra-low/low dose NCCT may be considered as additional options in the second and third trimesters.<sup>186,214,215</sup>

### *Management*

Most ureteral stones will pass spontaneously and the first option in management is conservative therapy, including hydration and analgesia.<sup>216</sup> NSAIDs should be avoided in pregnancy due to known fetal risks.<sup>217</sup> Data suggests MET with  $\alpha$ -blockers is relatively safe in this patient population, however, efficacy is currently not well established.<sup>218,219</sup> It should be noted that these medications are category B rated and should be used with caution, as an off-label adjunct.<sup>105</sup>

Immediate causes for intervention are the same as those in non-pregnant situations, but also includes induction of premature labour (contractions, fetal distress).<sup>220</sup> The immediate methods of intervention in these situations are NT or ureteral stent insertion. Although safe, the evidence for NT placement are comprised of small low-level studies.<sup>221–223</sup> In pregnancy, ureteral stents and NTs are at risk for accelerated encrustation thereby requiring changes every 4-6 weeks.<sup>224,225</sup>

Failing conservative management, URS using laser lithotripsy has been shown to be feasible and safe.<sup>226</sup> In fact, if ultrasound imaging is non-diagnostic and low-dose NCCT or MRI is unavailable, URS can also be used for both diagnostic and therapeutic purposes.<sup>227,228</sup> A number of studies have demonstrated that URS is a viable technique to treat stones in pregnancy.<sup>227,229–233</sup> Postoperative stenting following URS in this situation is recommended in an attempt to reduce postoperative complications.<sup>227,234</sup> With respect to safety of the pregnancy, traditional teaching was that URS should be undertaken during the second trimester,<sup>220,235</sup> but more recent literature suggests there is no evidence to support a “safest” trimester.<sup>221</sup>

With regards to intraoperative imaging, if URS or ureteral stent insertion is undertaken, then a lead apron or shield should be put between the x-ray fluoroscopy source and the fetus to shield it from radiation.<sup>236</sup> Alternatively, URS or ureteral stent insertion can be performed under ultrasound guidance alone, avoiding radiation exposure. Continuous fetal monitoring has been advocated during these interventions,<sup>212,220</sup> though may not always be necessary.

Pregnancy is a contraindication to SWL and although there have been reports of the inadvertent treatment of pregnant patients with SWL, with no adverse sequelae to the fetus,<sup>237</sup> it should be avoided. Similarly, antegrade URS should likely be delayed until after birth as the procedure may require prolonged anesthesia and radiation exposure. However, some case series of safe PCNL during pregnancy have been published.<sup>238</sup>

**Recommendation: First-line diagnostic testing for stones in pregnancy is US, but low-dose NCCT or MRI (without gadolinium in the first trimester) can also be used (level 3, strong recommendation). Obstructing ureteral stones in pregnancy can be managed conservatively in the absence of suspected or confirmed urinary infection (level 3, moderate recommendation). In pregnant patients presenting with signs of sepsis, antibiotics and urinary decompression via a**

**NT or ureteral stent are of primary importance; consultation with the obstetrics team is recommended. URS with laser lithotripsy is safe in pregnancy; however, SWL is contraindicated in pregnancy (level 2, strong recommendation).**

*Competing interests: Dr. Lee has received a speaker honorarium from Baxter. Dr. Bhojani has reviewed new products for Boston Scientific and participated in WATER 2, an Aquablation multi-institutional clinical trial supported by Procept. Dr. Chew has been a consultant for Auris Robotics, Bard Medical, Boston Scientific, and Olympus; has been a lecturer for Boston Scientific, Coloplast, Cook Medical, and Olympus; received a study grant from Boston Scientific; received a fellowship salary from Cook Medical; and participated in clinical trials supported by Boston Scientific and Cook Medical. Dr. Elmansy has received payment from Boston Scientific, Clarion Medical Technologies/AccuTech Medical Technologies, and Janssen; and received speaker honoraria and a travel grant from Lumenis. Dr. Pace has received support for a fellowship and annual lectureship from Cook Urological. The remaining author report no competing personal or financial interests related to this work.*

DRAFT

## References

1. Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in the United States. *Eur Urol*. 2012;62(1):160-165. doi:10.1016/j.eururo.2012.03.052
2. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. *World J Urol*. 2017;35(9):1301-1320. doi:10.1007/s00345-017-2008-6
3. Raheem OA, Khandwala YS, Sur RL, Ghani KR, Denstedt JD. Burden of Urolithiasis: Trends in Prevalence, Treatments, and Costs. *Eur Urol Focus*. 2017;3(1):18-26. doi:10.1016/j.euf.2017.04.001
4. Innes G, McRae A, Grafstein E, et al. Variability of renal colic management and outcomes in two Canadian cities. *Can J Emerg Med*. 2018;20(5):702-712. doi:10.1017/cem.2018.31
5. Dauw CA, Kaufman SR, Hollenbeck BK, et al. Expulsive therapy versus early endoscopic stone removal in patients with acute renal colic: A comparison of indirect costs. *J Urol*. 2014;191(3):673-677. doi:10.1016/j.juro.2013.09.028
6. Ordon M, Andonian S, Blew B, Schuler T, Chew B, Pace KT. CUA guideline: Management of ureteral calculi. *J Can Urol Assoc*. 2015;9(11-12December):E837-E851. doi:10.5489/cuaj.3483
7. Howick J, Chalmers I, Glasziou P, et al. *The Oxford Levels of Evidence 2*; 2011.
8. Skolarikos A, Laguna MP, Alivizatos G, Kural AR, De La Rosette JJMCH. The role for active monitoring in urinary stones: A systematic review. *J Endourol*. 2010;24(6):923-930. doi:10.1089/end.2009.0670
9. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. *J Urol*. 2005;174(1):167-172. doi:10.1097/01.ju.0000161600.54732.86
10. Ye Z, Yang H, Li H, et al. A multicentre, prospective, randomized trial: Comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic. *BJU Int*. 2011;108(2):276-279. doi:10.1111/j.1464-410X.2010.09801.x
11. Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy in adults with ureteric colic: A multicentre, randomised, placebo-controlled trial. *Lancet*. 2015;386(9991):341-349. doi:10.1016/S0140-6736(15)60933-3
12. Borofsky MS, Walter D, Shah O, Goldfarb DS, Mues AC, Makarov D V. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. *J Urol*. 2013;189(3):946-951. doi:10.1016/j.juro.2012.09.088
13. Haas CR, Smigelski M, Sebesta EM, Mobley D, Shah O. Implementation of a Hospital-Wide Protocol Reduces Time to Decompression and Length of Stay in Patients with Stone-Related Obstructive Pyelonephritis with Sepsis. *J Endourol*. September 2020. doi:10.1089/end.2020.0626
14. Varda B, Sood A, Krishna N, et al. National rates and risk factors for stent failure after successful insertion in patients with obstructed, infected upper tract stones. *J Can Urol Assoc*. 2015;9(3-4APRIL):E164-E171. doi:10.5489/cuaj.2456
15. Mokhmalji H, Braun PM, Martinez Portillo FJ, Siegsmond M, Alken P, Köhrmann KU. Percutaneous nephrostomy versus ureteral stents for diversion of hydronephrosis caused by stones: a prospective, randomized clinical trial. *J Urol*. 2001;165(4):1088-1092.
16. Pearle MS, Pierce HL, Miller GL, et al. Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. *J Urol*. 1998;160(4):1260-1264.
17. Christoph F, Weikert S, Müller M, Miller K, Schrader M. How septic is urosepsis? Clinical course of infected hydronephrosis and therapeutic strategies. *World J Urol*. 2005;23(4):243-247.

doi:10.1007/s00345-005-0002-x

18. Ramsey S, Robertson A, Ablett MJ, Meddings RN, Hollins GW, Little B. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. *J Endourol.* 2010;24(2):185-189. doi:10.1089/end.2009.0361
19. Yoshimura K, Utsunomiya N, Ichioka K, Ueda N, Matsui Y, Terai A. Emergency drainage for urosepsis associated with upper urinary tract calculi. *J Urol.* 2005;173(2):458-462. doi:10.1097/01.ju.0000150512.40102.bb
20. Shi YF, Ju WL, Zhu YP, Xia SJ, Sun XW. The impact of ureteral stent indwelling time on the treatment of acute infection caused by ureteral calculi. *Urolithiasis.* 2017;45(6):579-583. doi:10.1007/s00240-017-0964-3
21. Singer M, Deutschman CS, Seymour C, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA - J Am Med Assoc.* 2016;315(8):801-810. doi:10.1001/jama.2016.0287
22. Jennings CA, Khan Z, Sidhu P, et al. Management and outcome of obstructive ureteral stones in the emergency department: Emphasis on urine tests and antibiotics usage. *Am J Emerg Med.* 2019;37(10):1855-1859. doi:10.1016/j.ajem.2018.12.046
23. Kim HY, Choe HS, Lee DS, Yoo JM, Lee SJ. Transient renal impairment in the absence of pre-existing chronic kidney disease in patients with unilateral ureteric stone impaction. *Urolithiasis.* 2017;45(3):249-254. doi:10.1007/s00240-016-0904-7
24. Guercio S, Ambu A, Mangione F, Mari M, Vacca F, Bellina M. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. In: *Journal of Endourology.* Vol 25. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA ; 2011:1137-1141. doi:10.1089/end.2010.0554
25. Kumar A, Mohanty NK, Jain M, Prakash S, Arora RP. A prospective randomized comparison between early (<48 hours of onset of colicky pain) versus delayed shockwave lithotripsy for symptomatic upper ureteral calculi: A single center experience. *J Endourol.* 2010;24(12):2059-2066. doi:10.1089/end.2010.0066
26. Uguz S, Senkul T, Soydan H, et al. Immediate or delayed SWL in ureteric stones: A prospective and randomized study. *Urol Res.* 2012;40(6):739-744. doi:10.1007/s00240-012-0490-2
27. Westphalen AC, Hsia RY, Maselli JH, Wang R, Gonzales R. Radiological imaging of patients with suspected urinary tract stones: National trends, diagnoses, and predictors. *Acad Emerg Med.* 2011;18(7):699-707. doi:10.1111/j.1553-2712.2011.01103.x
28. Chang HC, Raskolnikov D, Dai JC, et al. National Imaging Trends in Nephrolithiasis—Does Renal Ultrasound in the Emergency Department Pave the Way for Computerized Tomography? *Urol Pract.* 2021;8(1):82-87. doi:10.1097/upj.0000000000000148
29. Innes GD, Scheuermeyer FX, Law MR, et al. Sex-related Differences in Emergency Department Renal Colic Management: Females Have Fewer Computed Tomography Scans but Similar Outcomes. *Acad Emerg Med.* 2016;23(10):1153-1160. doi:10.1111/acem.13041
30. Schoenfeld EM, Pekow PS, Shieh MS, Scales CD, Lagu T, Lindenauer PK. The diagnosis and management of patients with renal colic across a sample of us hospitals: High CT utilization despite low rates of admission and inpatient urologic intervention. *PLoS One.* 2017;12(1). doi:10.1371/journal.pone.0169160
31. Smith-Bindman R, Aubin C, Bailitz J, et al. Ultrasonography versus Computed Tomography for Suspected Nephrolithiasis. *N Engl J Med.* 2014;371(12):1100-1110. doi:10.1056/nejmoa1404446

32. Ripollés T, Agramunt M, Errando J, Martínez MJ, Coronel B, Morales M. Suspected ureteral colic: Plain film and sonography vs unenhanced helical CT. A prospective study in 66 patients. *Eur Radiol.* 2004;14(1):129-136. doi:10.1007/s00330-003-1924-6
33. Foell K, Ordon M, Ghiculete D, Lee JY, Honey RJDA, Pace KT. Does baseline radiography of the kidneys, ureters, and bladder help facilitate stone management in patients presenting to the emergency department with renal colic? *J Endourol.* 2013;27(12):1425-1430. doi:10.1089/end.2013.0183
34. Gervaise A, Naulet P, Beuret F, et al. Low-Dose CT With Automatic Tube Current Modulation, Adaptive Statistical Iterative Reconstruction, and Low Tube Voltage for the Diagnosis of Renal Colic: Impact of Body Mass Index. *Am J Roentgenol.* 2014;202(3):553-560. doi:10.2214/AJR.13.11350
35. McLaughlin PD, Mallinson P, Lourenco P, Nicolaou S. Dual-Energy Computed Tomography: Advantages in the Acute Setting. *Radiol Clin North Am.* 2015;53(4):619-638. doi:10.1016/j.rcl.2015.02.016
36. Sur RL, Shore N, L'Esperance J, et al. Silodosin to facilitate passage of ureteral stones: A multi-institutional, randomized, double-blinded, placebo-controlled trial. *Eur Urol.* 2015;67(5):959-964. doi:10.1016/j.eururo.2014.10.049
37. Furyk JS, Chu K, Banks C, et al. Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial. *Ann Emerg Med.* 2016;67(1):86-95.e2. doi:10.1016/j.annemergmed.2015.06.001
38. Cui Y, Chen J, Zeng F, et al. Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Urol.* 2019;201(5):950-955. doi:10.1097/JU.0000000000000029
39. Hollingsworth JM, Canales BK, Rogers MAM, et al. Alpha blockers for treatment of ureteric stones: Systematic review and meta-analysis. *BMJ.* 2016;355. doi:10.1136/bmj.i6112
40. Amer T, Osman B, Johnstone A, et al. Medical expulsive therapy for ureteric stones: Analysing the evidence from systematic reviews and meta-analysis of powered double-blinded randomised controlled trials. *Arab J Urol.* 2017;15(2):83-93. doi:10.1016/j.aju.2017.03.005
41. Ye Z, Zeng G, Yang H, et al. Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial [Figure presented]. *Eur Urol.* 2018;73(3):385-391. doi:10.1016/j.eururo.2017.10.033
42. Türk C, Knoll T, Seitz C, Skolarikos A, Chapple C, McClinton S. Medical Expulsive Therapy for Ureterolithiasis: The EAU Recommendations in 2016. *Eur Urol.* 2017;71(4):504-507. doi:10.1016/j.eururo.2016.07.024
43. Campschroer T, Zhu X, Vernooij RWM, Lock MTWT. Alpha-blockers as medical expulsive therapy for ureteral stones. *Cochrane Database Syst Rev.* 2018;2018(4). doi:10.1002/14651858.CD008509.pub3
44. Rui P, Santo L, Ashman JJ. Trends in Opioids Prescribed at Discharge From Emergency Departments Among Adults: United States, 2006-2017. *Natl Heal Stat Rep.* 2020;135:1-12.
45. Pathan SA, Mitra B, Straney LD, et al. Delivering safe and effective analgesia for management of renal colic in the emergency department: A double-blind, multigroup, randomised controlled trial. *Lancet.* 2016;387(10032):1999-2007. doi:10.1016/S0140-6736(16)00652-8
46. Minhaj FS, Hoang-Nguyen M, Tenney A, et al. Evaluation of opioid requirements in the management of renal colic after guideline implementation in the emergency department. *Am J Emerg Med.* 2020;38(12):2564-2569. doi:10.1016/j.ajem.2019.12.042

47. Leapman MS, Derycke E, Skanderson M, et al. Variation in national opioid prescribing patterns following surgery for kidney stones. *Pain Med (United States)*. 2018;19(suppl\_1):S12-S18. doi:10.1093/pm/pny125
48. Taenzer P, Melzack R, Jeans ME. Influence of psychological factors on postoperative pain, mood and analgesic requirements. *Pain*. 1986;24(3):331-342. doi:10.1016/0304-3959(86)90119-3
49. Worster AS, Bhanich Supapol W. Fluids and diuretics for acute ureteric colic. *Cochrane Database Syst Rev*. 2012;(2). doi:10.1002/14651858.cd004926.pub3
50. Meltzer AC, Burrows PK, Kirkali Z, et al. Accuracy of Patient Reported Stone Passage for Patients With Acute Renal Colic Treated in the Emergency Department. *Urology*. 2020;136:70-74. doi:10.1016/j.urology.2019.10.010
51. McLarty R, Assmus M, Senthilselvan A, Schuler T, Wollin T, De S. Patient Reported Outcomes Predicting Spontaneous Stone Passage May Not Have Acceptable Accuracy. *J Urol*. 2020;204(3):524-530. doi:10.1097/JU.0000000000001030
52. Cheng RZ, Shkolyar E, Chang TC, et al. Ultra-Low-Dose CT: An Effective Follow-Up Imaging Modality for Ureterolithiasis. *J Endourol*. 2020;34(2):139-144. doi:10.1089/end.2019.0574
53. Horne KL, Packington R, Monaghan J, Reilly T, Selby NM. Three-year outcomes after acute kidney injury: Results of a prospective parallel group cohort study. *BMJ Open*. 2017;7(3). doi:10.1136/bmjopen-2016-015316
54. Meldrum KK. Pathophysiology of urinary tract obstruction. In: *Campbell-Walsh Urology*. Philadelphia: Saunders; 2015:1101-1102.
55. Saw KC, Lingemann JE. Lesson 20: Management of Calyceal Stones. 1999:154-159.
56. Gupta NP, Ansari MS, Kesarvani P, Kapoor A, Mukhopadhyay S. Role of computed tomography with no contrast medium enhancement in predicting the outcome of extracorporeal shock wave lithotripsy for urinary calculi. *BJU Int*. 2005;95(9):1285-1288. doi:10.1111/j.1464-410X.2005.05520.x
57. Joseph P, Mandal AK, Singh SK, Mandal P, Sankhwar SN, Sharma SK. Computerized tomography attenuation value of renal calculus: Can it predict successful fragmentation of the calculus by extracorporeal shock wave lithotripsy? A preliminary study. *J Urol*. 2002;167(5):1968-1971. doi:10.1016/S0022-5347(05)65064-1
58. Abdelhamid M, Mosharafa AA, Ibrahim H, et al. A Prospective Evaluation of High-Resolution CT Parameters in Predicting Extracorporeal Shockwave Lithotripsy Success for Upper Urinary Tract Calculi. *J Endourol*. 2016;30(11):1227-1232. doi:10.1089/end.2016.0364
59. El-Nahas AR, El-Assmy AM, Mansour O, Sheir KZ. A Prospective Multivariate Analysis of Factors Predicting Stone Disintegration by Extracorporeal Shock Wave Lithotripsy: The Value of High-Resolution Noncontrast Computed Tomography. *Eur Urol*. 2007;51(6):1688-1694. doi:10.1016/j.eururo.2006.11.048
60. Ouzaid I, Al-Qahtani S, Dominique S, et al. A 970 Hounsfield units (HU) threshold of kidney stone density on non-contrast computed tomography (NCCT) improves patients' selection for extracorporeal shockwave lithotripsy (ESWL): Evidence from a prospective study. *BJU Int*. 2012;110(11 B). doi:10.1111/j.1464-410X.2012.10964.x
61. Yamashita S, Kohjimoto Y, Iguchi T, et al. Variation coefficient of stone density: A novel predictor of the outcome of extracorporeal shockwave lithotripsy. *J Endourol*. 2017;31(4):384-390. doi:10.1089/end.2016.0719
62. Perks AE, Schuler TD, Lee J, et al. Stone Attenuation and Skin-to-Stone Distance on Computed Tomography Predicts for Stone Fragmentation by Shock Wave Lithotripsy. *Urology*. 2008;72(4):765-769. doi:10.1016/j.urology.2008.05.046

63. Wiesenthal JD, Ghiculete D, John D'A Honey R, Pace KT. Evaluating the importance of mean stone density and skin-to-stone distance in predicting successful shock wave lithotripsy of renal and ureteric calculi. In: *Urological Research*. Vol 38. Urol Res; 2010:307-313. doi:10.1007/s00240-010-0295-0
64. Pareek G, Hedican SP, Lee FT, Nakada SY. Shock wave lithotripsy success determined by skin-to-stone distance on computed tomography. *Urology*. 2005;66(5):941-944. doi:10.1016/j.urology.2005.05.011
65. Müllhaupt G, Engeler DS, Schmid HP, Abt D. How do stone attenuation and skin-to-stone distance in computed tomography influence the performance of shock wave lithotripsy in ureteral stone disease? *BMC Urol*. 2015;15(1):72. doi:10.1186/s12894-015-0069-7
66. Wiesenthal JD, Ghiculete D, Ray AA, Honey RJDA, Pace KT. A clinical nomogram to predict the successful shock wave lithotripsy of renal and ureteral calculi. *J Urol*. 2011;186(2):556-562. doi:10.1016/j.juro.2011.03.109
67. Patel T, Kozakowski K, Hruby G, Gupta M. Skin to stone distance is an independent predictor of stone-free status following shockwave lithotripsy. *J Endourol*. 2009;23(9):1383-1385. doi:10.1089/end.2009.0394
68. McAteer JA, Evan AR, Williams JC, Lingeman JE. Treatment protocols to reduce renal injury during shock wave lithotripsy. *Curr Opin Urol*. 2009;19(2):192-195. doi:10.1097/MOU.0b013e32831e16e3
69. Lambert EH, Walsh R, Moreno MW, Gupta M. Effect of Escalating Versus Fixed Voltage Treatment on Stone Comminution and Renal Injury During Extracorporeal Shock Wave Lithotripsy: A Prospective Randomized Trial. *J Urol*. 2010;183(2):580-584. doi:10.1016/j.juro.2009.10.025
70. Willis LR, Evan AP, Connors BA, Handa RK, Blomgren PM, Lingeman JE. Prevention of lithotripsy-induced renal injury by pretreating kidneys with low-energy shock waves. *J Am Soc Nephrol*. 2006;17(3):663-673. doi:10.1681/ASN.2005060634
71. Weizer AZ, Zhong P, Preminger GM. New Concepts in Shock Wave Lithotripsy. *Urol Clin North Am*. 2007;34(3):375-382. doi:10.1016/j.ucl.2007.07.002
72. Seemann O, Rassweiler J, Chvapil M, Alken P, Drach GW. The effect of single shock waves on the vascular system of artificially perfused rabbit kidneys. *J Stone Dis*. 1993;5(3):172-178.
73. PACE KT, WEIR MJ, TARIQ N, HONEY RJD. LOW SUCCESS RATE OF REPEAT SHOCK WAVE LITHOTRIPSY FOR URETERAL STONES AFTER FAILED INITIAL TREATMENT. *J Urol*. 2000;164(6):1905-1907. doi:10.1016/S0022-5347(05)66914-5
74. Rassweiler JJ, Knoll T, Köhrmann KU, et al. Shock wave technology and application: An update. *Eur Urol*. 2011;59(5):784-796. doi:10.1016/j.eururo.2011.02.033
75. Pace KT, Ghiculete D, Harju M, Honey RJDA. Shock wave lithotripsy at 60 or 120 shocks per minute: A randomized, double-blind trial. *J Urol*. 2005;174(2):595-599. doi:10.1097/01.ju.0000165156.90011.95
76. Honey RJD 'A., Schuler TD, Ghiculete D, Pace KT. A Randomized, Double-Blind Trial to Compare Shock Wave Frequencies of 60 and 120 Shocks per Minute for Upper Ureteral Stones. *J Urol*. 2009;182(4):1418-1423. doi:10.1016/j.juro.2009.06.019
77. Davenport K, Minervini A, Keoghane S, Parkin J, Keeley FX, Timoney AG. Does Rate Matter? The Results of a Randomized Controlled Trial of 60 Versus 120 Shocks per Minute for Shock Wave Lithotripsy of Renal Calculi. *J Urol*. 2006;176(5):2055-2058. doi:10.1016/j.juro.2006.07.012
78. Madbouly K, El-Tiraifi AM, Seida M, El-Faqih SR, Atassi R, Talic RF. Slow versus fast

- shock wave lithotripsy rate for urolithiasis: A prospective randomized study. *J Urol*. 2005;173(1):127-130. doi:10.1097/01.ju.0000147820.36996.86
79. Yilmaz E, Batislam E, Basar M, Tuglu D, Mert C, Basar H. Optimal frequency in extracorporeal shock wave lithotripsy: Prospective randomized study. *Urology*. 2005;66(6):1160-1164. doi:10.1016/j.urology.2005.06.111
80. Li K, Lin T, Zhang C, et al. Optimal frequency of shock wave lithotripsy in urolithiasis treatment: A systematic review and meta-analysis of randomized controlled trials. *J Urol*. 2013;190(4):1260-1267. doi:10.1016/j.juro.2013.03.075
81. Kato Y, Yamaguchi S, Hori J, Okuyama M, Kakizaki H. Improvement of stone comminution by slow delivery rate of shock waves in extracorporeal lithotripsy. *Int J Urol*. 2006;13(12):1461-1465. doi:10.1111/j.1442-2042.2006.01609.x
82. Chacko J, Moore M, Sankey N, Chandhoke PS. Does a slower treatment rate impact the efficacy of extracorporeal shock wave lithotripsy for solitary kidney or ureteral stones? *J Urol*. 2006;175(4):1370-1374. doi:10.1016/S0022-5347(05)00683-X
83. Kang DH, Cho KS, Ham WS, et al. Comparison of High, Intermediate, and Low Frequency Shock Wave Lithotripsy for Urinary Tract Stone Disease: Systematic Review and Network Meta-Analysis. Tu Y-K, ed. *PLoS One*. 2016;11(7):e0158661. doi:10.1371/journal.pone.0158661
84. López-Acón JD, Alba AB, Bahílo-Mateu P, et al. Analysis of the Efficacy and Safety of Increasing the Energy Dose Applied per Session by Increasing the Number of Shock Waves in Extracorporeal Lithotripsy: A Prospective and Comparative Study. *J Endourol*. 2017;31(12):1289-1294. doi:10.1089/end.2017.0261
85. Budía Alba A, López Acón JD, Polo-Rodrigo A, Bahílo-Mateu P, Trassierra-Villa M, Boronat-Tormo F. Analysis of the safety profile of treatment with a large number of shock waves per session in extracorporeal lithotripsy. *Actas Urol Esp*. 2015;39(5):291-295.
86. Eryildirim B, Sahin C, Tuncer M, Sabuncu K, Tarhan F, Sarica K. Medical Expulsive Therapy Following Shock Wave Lithotripsy in Ureteral Calculi: An Effective Approach for the Improvement of Health-Related Quality of Life. *Urol Int*. 2016;97(3):260-265. doi:10.1159/000446002
87. Ahmed A, Shalaby E, El-feky M, et al. Role of Tamsulosin Therapy after Extracorporeal Shockwave Lithotripsy for Renal Stones: Randomized Controlled Trial. *Urol Int*. 2016;97(3):266-272. doi:10.1159/000445840
88. De Nunzio C, Brassetti A, Bellangino M, et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: A short-term follow-up randomized, placebo-controlled study. *J Endourol*. 2016;30(7):817-821. doi:10.1089/end.2016.0113
89. Schuler TD, Shahani R, Honey RJDA, Pace KT. Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: A systematic review and meta-analysis. *J Endourol*. 2009;23(3):387-393. doi:10.1089/end.2008.0216
90. Bhagat SK, Chacko NK, Kekre NS, Gopalakrishnan G, Antonisamy B, Devasia A. Is There a Role for Tamsulosin in Shock Wave Lithotripsy for Renal and Ureteral Calculi? *J Urol*. 2007;177(6):2185-2188. doi:10.1016/j.juro.2007.01.160
91. Gravina GL, Costa AM, Ronchi P, et al. Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. *Urology*. 2005;66(1):24-28. doi:10.1016/j.urology.2005.01.013
92. Porpiglia F, Destefanis P, Fiori C, Scarpa RM, Fontana D. Role of adjunctive medical therapy with nifedipine and deflazacort after extracorporeal shock wave lithotripsy of ureteral stones. *Urology*. 2002;59(6):835-838. doi:10.1016/S0090-4295(02)01553-4

93. Skolarikos A, Grivas N, Kallidonis P, et al. The Efficacy of Medical Expulsive Therapy (MET) in Improving Stone-free Rate and Stone Expulsion Time, after Extracorporeal Shock Wave Lithotripsy (SWL) for Upper Urinary Stones: A Systematic Review and Meta-analysis. *Urology*. 2015;86(6):1057-1064. doi:10.1016/j.urology.2015.09.004
94. Li M, Wang Z, Yang J, et al. Adjunctive medical therapy with innodataalpha-blocker after extracorporeal shock wave lithotripsy of renal and ureteral stones:A meta-analysis. *PLoS One*. 2015;10(4). doi:10.1371/journal.pone.0122497
95. Chen K, Mi H, Xu G, et al. The efficacy and safety of tamsulosin combined with extracorporeal shockwave lithotripsy for urolithiasis: A systematic review and meta-analysis of randomized controlled trials. *J Endourol*. 2015;29(10):1166-1176. doi:10.1089/end.2015.0098
96. Ouyang W, Sun G, Long G, et al. Adjunctive medical expulsive therapy with tamsulosin for repeated extracorporeal shock wave lithotripsy: a systematic review and meta-analysis. *Int Braz J Urol*. 2020;47(1):23-35. doi:10.1590/S1677-5538.IBJU.2020.0093
97. Oestreich MC, Sathianathen NJ, Hwang EC, et al. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. *Cochrane Database Syst Rev*. 2019;2019(8). doi:10.1002/14651858.CD013393
98. Musa AAK. Use of double-J stents prior to extracorporeal shock wave lithotripsy is not beneficial: Results of a prospective randomized study. *Int Urol Nephrol*. 2008;40(1):19-22. doi:10.1007/s11255-006-9030-8
99. Pettenati C, Fegoun AB El, Hupertan V, Dominique S, Ravery V. Double J stent reduces the efficacy of extracorporeal shock wave lithotripsy in the treatment of lumbar ureteral stones. *Cent Eur J Urol*. 2013;66(3):309-313. doi:10.5173/cej.2013.03.art14
100. Pengfei S, Min J, Jie Y, et al. Use of ureteral stent in extracorporeal shock wave lithotripsy for upper urinary calculi: A systematic review and meta-analysis. *J Urol*. 2011;186(4):1328-1335. doi:10.1016/j.juro.2011.05.073
101. Wang H, Man L, Li G, Huang G, Liu N, Wang J. Meta-analysis of stenting versus non-stenting for the treatment of ureteral stones. *PLoS One*. 2017;12(1). doi:10.1371/journal.pone.0167670
102. Sfoungaristos S, Polimeros N, Kavouras A, Perimenis P. Stenting or not prior to extracorporeal shockwave lithotripsy for ureteral stones? Results of a prospective randomized study. *Int Urol Nephrol*. 2012;44(3):731-737. doi:10.1007/s11255-011-0062-3
103. Lucio II J, Korkeas F, Lopes-Neto AC, Silva EG, Mattos MHE, Pompeo ACL. Steinstrasse predictive factors and outcomes after extracorporeal shockwave lithotripsy. *Int braz j urol*. 2011;37(4):477-482. doi:10.1590/s1677-55382011000400006
104. Duvdevani M, Lorber G, Gofrit ON, et al. Fever after shockwave lithotripsy-risk factors and indications for prophylactic antimicrobial treatment. *J Endourol*. 2010;24(2):277-281. doi:10.1089/end.2009.0283
105. Assimos D, Krambeck A, Miller NL, et al. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART I. *J Urol*. 2016;196(4):1153-1160. doi:10.1016/j.juro.2016.05.090
106. Alsaikhan B, Koziarz A, Lee JY, Pace KT. Preoperative Alpha-Blockers for Ureteroscopy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Endourol*. 2020;34(1):33-41. doi:10.1089/end.2019.0520
107. Brisbane W, Bailey MR, Sorensen MD. An overview of kidney stone imaging techniques. *Nat Rev Urol*. 2016;13(11):654-662. doi:10.1038/nrurol.2016.154
108. Chew BH, Brotherhood HL, Sur RL, et al. Natural History, Complications and Re-

- Intervention Rates of Asymptomatic Residual Stone Fragments after Ureteroscopy: a Report from the EDGE Research Consortium. *J Urol*. 2016;195(4):982-986. doi:10.1016/j.juro.2015.11.009
109. Beiko DT, Beasley KA, Koka PK, et al. Upper tract imaging after ureteroscopic holmium:YAG laser lithotripsy: when is it necessary? *Can J Urol*. 2003;10(6):2062-2067.
110. Sutherland TN, Pearle MS, Lotan Y. How much is a kidney worth? Cost-effectiveness of routine imaging after ureteroscopy to prevent silent obstruction. *J Urol*. 2013;189(6):2136-2141. doi:10.1016/j.juro.2012.12.059
111. Weizer AZ, Auge BK, Silverstein AD, et al. *ROUTINE POSTOPERATIVE IMAGING IS IMPORTANT AFTER URETEROSCOPIC STONE MANIPULATION.*; 2002.
112. May PC, Hsi RS, Tran H, et al. The Morbidity of Ureteral Strictures in Patients with Prior Ureteroscopic Stone Surgery: Multi-Institutional Outcomes. *J Endourol*. 2018;32(4):309-314. doi:10.1089/end.2017.0657
113. Traxer O, Thomas A. Prospective evaluation and classification of ureteral wall injuries resulting from insertion of a ureteral access sheath during retrograde intrarenal surgery. *J Urol*. 2013;189(2):580-584. doi:10.1016/j.juro.2012.08.197
114. Traxer O, Wendt-Nordahl G, Sodha H, et al. Differences in renal stone treatment and outcomes for patients treated either with or without the support of a ureteral access sheath: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study. *World J Urol*. 2015;33(12):2137-2144. doi:10.1007/s00345-015-1582-8
115. Huang J, Zhao Z, AlSmadi JK, et al. Use of the ureteral access sheath during ureteroscopy: A systematic review and meta-analysis. Gao X, ed. *PLoS One*. 2018;13(2):e0193600. doi:10.1371/journal.pone.0193600
116. De Coninck V, Keller EX, Rodríguez-Monsalve M, Audouin M, Doizi S, Traxer O. Systematic review of ureteral access sheaths: facts and myths. *BJU Int*. 2018;122(6):959-969. doi:10.1111/bju.14389
117. Stern KL, Loftus CJ, Doizi S, Traxer O, Monga M. A Prospective Study Analyzing the Association between High-Grade Ureteral Access Sheath Injuries and the Formation of Ureteral Strictures. *J Urol*. 2019;202(3):454. doi:10.1016/j.urol.2019.02.032
118. Cetti RJ, Biers S, Keoghane SR. The difficult ureter: What is the incidence of pre-stenting? *Ann R Coll Surg Engl*. 2011;93(1):31-33. doi:10.1308/003588411X12851639106990
119. Assimos D, Crisci A, Culkin D, et al. Preoperative JJ stent placement in ureteric and renal stone treatment: Results from the Clinical Research Office of Endourological Society (CROES) ureteroscopy (URS) Global Study. *BJU Int*. 2016;117(4):648-654. doi:10.1111/bju.13250
120. Jessen JP, Breda A, Brehmer M, et al. International Collaboration in Endourology: Multicenter Evaluation of Pre-stenting for Ureterorenoscopy. *J Endourol*. 2016;30(3):268-273. doi:10.1089/end.2015.0109
121. Netsch C, Knipper S, Bach T, Herrmann TRW, Gross AJ. Impact of preoperative ureteral stenting on stone-free rates of ureteroscopy for nephroureterolithiasis: A matched-paired analysis of 286 patients. *Urology*. 2012;80(6):1214-1220. doi:10.1016/j.urol.2012.06.064
122. Chu L, Farris CA, Corcoran AT, Averch TD. Preoperative stent placement decreases cost of ureteroscopy. *Urology*. 2011;78(2):309-313. doi:10.1016/j.urol.2011.03.055
123. Chu L, Sternberg KM, Averch TD. Preoperative stenting decreases operative time and reoperative rates of ureteroscopy. *J Endourol*. 2011;25(5):751-754. doi:10.1089/end.2010.0400
124. Pengfei S, Yutao L, Jie Y, et al. The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: A systematic review and meta-analysis. *J Urol*. 2011;186(5):1904-1909. doi:10.1016/j.juro.2011.06.066

125. Ordonez M, Hwang EC, Borofsky M, Bakker CJ, Gandhi S, Dahm P. Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi. *Cochrane Database Syst Rev*. 2019;2019(2). doi:10.1002/14651858.CD012703.pub2
126. Pais VM, Smith RE, Stedina EA, Rissman CM. Does Omission of Ureteral Stents Increase Risk of Unplanned Return Visit? A Systematic Review and Meta-Analysis. *J Urol*. 2016;196(5):1458-1466. doi:10.1016/j.juro.2016.05.109
127. Mittakanti HR, Conti SL, Pao AC, et al. Unplanned Emergency Department Visits and Hospital Admissions Following Ureteroscopy: Do Ureteral Stents Make a Difference? *Urology*. 2018;117:44-49. doi:10.1016/j.urology.2018.03.019
128. Torricelli FC, De S, Hinck B, Noble M, Monga M. Flexible ureteroscopy with a ureteral access sheath: When to stent? *Urology*. 2014;83(2):278-281. doi:10.1016/j.urology.2013.10.002
129. Rapoport D, Perks AE, Teichman JMH. Ureteral access sheath use and stenting in ureteroscopy: Effect on unplanned emergency room visits and cost. *J Endourol*. 2007;21(9):993-997. doi:10.1089/end.2006.0236
130. Cevik I, Dillioglulugil O, Akdas A, Siegel Y. Is stent placement necessary after uncomplicated ureteroscopy for removal of impacted ureteral stones? *J Endourol*. 2010;24(8):1263-1267. doi:10.1089/end.2009.0153
131. Denstedt JD, Wollin TA, Sofer M, Nott L, Weir M, John D'A Honey R. A prospective randomized controlled trial comparing nonstented versus stented ureteroscopic lithotripsy. *J Urol*. 2001;165(5):1419-1422.
132. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: A prospective study. *J Endourol*. 2008;22(4):651-655. doi:10.1089/end.2007.0257
133. EL-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. *World J Urol*. 2016;34(7):963-968. doi:10.1007/s00345-015-1704-3
134. Lallas CD, Auge BK, Raj G V., Santa-Cruz R, Madden JF, Preminger GM. Laser Doppler flowmetric determination of ureteral blood flow after ureteral access sheath placement. *J Endourol*. 2002;16(8):583-590. doi:10.1089/089277902320913288
135. Paul CJ, Brooks NA, Ghareeb GM, Tracy CR. Pilot Study to Determine Optimal Stent Duration Following Ureteroscopy: Three versus Seven days. *Curr Urol*. 2017;11(2):97-102. doi:10.1159/000447201
136. Kumar A, Nanda B, Kumar N, Kumar R, Vasudeva P, Mohanty NK. A prospective randomized comparison between shockwave lithotripsy and semirigid ureteroscopy for upper ureteral stones <2cm: A single center experience. *J Endourol*. 2015;29(1):47-51. doi:10.1089/end.2012.0493
137. Scotland KB, Safaee Ardekani G, Chan JYH, Paterson RF, Chew BH. Total Surface Area Influences Stone Free Outcomes in Shock Wave Lithotripsy for Distal Ureteral Calculi. *J Endourol*. 2019;33(8):661-666. doi:10.1089/end.2019.0120
138. Hautmann S, Friedrich MG, Fernandez S, et al. Extracorporeal shockwave lithotripsy compared with ureteroscopy for the removal of small distal ureteral stones. *Urol Int*. 2004;73(3):238-243. doi:10.1159/000080834
139. Verze P, Imbimbo C, Cangelmo G, et al. Extracorporeal shockwave lithotripsy vs ureteroscopy as first-line therapy for patients with single, distal ureteric stones: A prospective randomized study. *BJU Int*. 2010;106(11):1748-1752. doi:10.1111/j.1464-410X.2010.09338.x
140. Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE. Treatment of ureteral and

- renal stones: A systematic review and meta-analysis of randomized, controlled trials. *J Urol.* 2012;188(1):130-137. doi:10.1016/j.juro.2012.02.2569
141. Drake T, Grivas N, Dabestani S, et al. What are the Benefits and Harms of Ureteroscopy Compared with Shock-wave Lithotripsy in the Treatment of Upper Ureteral Stones? A Systematic Review. *Eur Urol.* 2017;72(5):772-786. doi:10.1016/j.eururo.2017.04.016
142. Rebuck DA, Coleman S, Chen JF, Casey JT, Perry KT, Nadler RB. Extracorporeal shockwave lithotripsy versus ureteroscopy: A comparison of intraoperative radiation exposure during the management of nephrolithiasis. *J Endourol.* 2012;26(6):597-601. doi:10.1089/end.2011.0185
143. Cone EB, Pareek G, Ursiny M, Eisner B. Cost-effectiveness comparison of ureteral calculi treated with ureteroscopic laser lithotripsy versus shockwave lithotripsy. *World J Urol.* 2017;35(1):161-166. doi:10.1007/s00345-016-1842-2
144. Constanti M, Calvert RC, Thomas K, Dickinson A, Carlisle S. Cost analysis of ureteroscopy (URS) vs extracorporeal shockwave lithotripsy (ESWL) in the management of ureteric stones <10 mm in adults: a UK perspective. *BJU Int.* 2020;125(3):457-466. doi:10.1111/bju.14938
145. Penniston KL, Nakada SY. Health Related Quality of Life Differs Between Male and Female Stone Formers. *J Urol.* 2007;178(6):2435-2440. doi:10.1016/j.juro.2007.08.009
146. Diniz DHMP, Blay SL, Schor N. Quality of life of patients with nephrolithiasis and recurrent painful renal colic. *Nephron - Clin Pract.* 2007;106(3). doi:10.1159/000102995
147. Bensalah K, Tuncel A, Gupta A, Raman JD, Pearle MS, Lotan Y. Determinants of Quality of Life for Patients With Kidney Stones. *J Urol.* 2008;179(6):2238-2243. doi:10.1016/j.juro.2008.01.116
148. Donnally CJ, Gupta A, Bensalah K, et al. Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones. *Urol Res.* 2011;39(2):141-146. doi:10.1007/s00240-010-0313-2
149. Bryant M, Angell J, Tu H, Goodman M, Pattaras J, Ogan K. Health related quality of life for stone formers. *J Urol.* 2012;188(2):436-440. doi:10.1016/j.juro.2012.04.015
150. Chandrasekar T, Monga M, Nguyen M, Low RK. Internet-Based Patient Survey on Urolithiasis Treatment and Patient Satisfaction. *J Endourol.* 2015;29(6):725-729. doi:10.1089/end.2014.0643
151. Park J, Shin DW, Chung JH, Lee SW. Shock wave lithotripsy versus ureteroscopy for ureteral calculi: A prospective assessment of patient-reported outcomes. *World J Urol.* 2013;31(6):1569-1574. doi:10.1007/s00345-012-0966-2
152. Lee JH, Woo SH, Kim ET, Kim DK, Park J. Comparison of patient satisfaction with treatment outcomes between ureteroscopy and shock wave lithotripsy for proximal ureteral stones. *Korean J Urol.* 2010;51(11):788-793. doi:10.4111/kju.2010.51.11.788
153. Ghalayini IF, Al-Ghazo MA, Khader YS. Extracorporeal shockwave lithotripsy versus ureteroscopy for distal ureteric calculi: Efficacy and patient satisfaction. *Int Braz J Urol.* 2006;32(6):656-664. doi:10.1590/s1677-55382006000600006
154. Rabah DM, Alomar M, Binsaleh S, Arafa MA. Health related quality of life in ureteral stone patients: Post-ureterolithiasis. *Urol Res.* 2011;39(5):385-388. doi:10.1007/s00240-011-0375-9
155. Izamin I, Aniza I, Rizal AM, Aljunid SM. Comparing extracorporeal shock wave lithotripsy and ureteroscopy for treatment of proximal ureteric calculi: A cost-effectiveness study. *Med J Malaysia.* 2009;64(1):12-21.
156. Hamamoto S, Unno R, Taguchi K, et al. Determinants of health-related quality of life for patients after urinary lithotripsy: ureteroscopic vs. shock wave lithotripsy. *Urolithiasis.*

2018;46(2):203-210. doi:10.1007/s00240-017-0972-3

157. Ceylan Y, Ucer O, Bozkurt O, et al. The effect of SWL and URS on health-related quality of life in proximal ureteral stones. *Minim Invasive Ther Allied Technol.* 2018;27(3):148-152.

doi:10.1080/13645706.2017.1350719

158. Raja A, Hekmati Z, Joshi HB. How do urinary calculi influence health-related quality of life and patient treatment preference: A systematic review. *J Endourol.* 2016;30(7):727-743.

doi:10.1089/end.2016.0110

159. Alsaikhan B, Andonian S. Shock wave lithotripsy in patients requiring anticoagulation or antiplatelet agents. *J Can Urol Assoc.* 2011;5(1):53-57. doi:10.5489/cuaj.09140

160. Aboumarzouk OM, Somani BK, Monga M. Flexible ureteroscopy and Holmium:YAG laser lithotripsy for stone disease in patients with bleeding diathesis: A systematic review of the literature. *Int Braz J Urol.* 2012;38(3):298-305. doi:10.1590/S1677-55382012000300002

161. Klingler HC, Kramer G, Lodde M, Dorfinger K, Hofbauer J, Marberger M. Stone treatment and coagulopathy. *Eur Urol.* 2003;43(1):75-79. doi:10.1016/S0302-2838(02)00538-9

162. Razvi H, Fuller A, Nott L, et al. Risk factors for perinephric hematoma formation after shockwave lithotripsy: A matched case-control analysis. *J Endourol.* 2012;26(11):1478-1482.

doi:10.1089/end.2012.0261

163. Tsuboi T, Fujita T, Maru N, Matsumoto K, Iwamura M, Baba S. Transurethral ureterolithotripsy and extracorporeal shock wave lithotripsy in patients with idiopathic thrombocytopenic purpura. *Acta Urol Jpn.* 2008;54(1):17-22.

164. Kaatz S, Paje D. Update in bridging anticoagulation. In: *Journal of Thrombosis and Thrombolysis.* Vol 31. J Thromb Thrombolysis; 2011:259-264. doi:10.1007/s11239-011-0571-z

165. Schregel C, John H, Randazzo M, Keller I. Influence of acetylsalicylic acid and low-molecular weight heparins on the formation of renal hematoma after shock wave lithotripsy. *World J Urol.* 2017;35(12):1939-1946. doi:10.1007/s00345-017-2070-0

166. Schnabel MJ, Gierth M, Bründl J, Chaussy CG, Burger M, Fritsche HM. Antiplatelet and anticoagulative medication during shockwave lithotripsy. *J Endourol.* 2014;28(9):1034-1039.

doi:10.1089/end.2014.0162

167. Kuo RL, Aslan P, Fitzgerald KB, Preminger GM. Use of ureteroscopy and holmium:YAG laser in patients with bleeding diatheses. *Urology.* 1998;52(4):609-613. doi:10.1016/S0090-4295(98)00276-3

168. Watterson JD, Girvan AR, Cook AJ, et al. Safety and efficacy of holmium:YAG laser lithotripsy in patients with bleeding diatheses. *J Urol.* 2002;168(2):442-445. doi:10.1016/S0022-5347(05)64654-X

169. Turna B, Stein RJ, Smaldone MC, et al. Safety and Efficacy of Flexible Ureterorenoscopy and Holmium:YAG Lithotripsy for Intrarenal Stones in Anticoagulated Cases. *J Urol.*

2008;179(4):1415-1419. doi:10.1016/j.juro.2007.11.076

170. Sharaf A, Amer T, Somani BK, Aboumarzouk OM. Ureteroscopy in Patients with Bleeding Diatheses, Anticoagulated, and on Anti-Platelet Agents: A Systematic Review and Meta-Analysis of the Literature. *J Endourol.* 2017;31(12):1217-1225. doi:10.1089/end.2017.0253

171. Elkoushy MA, Violette PD, Andonian S. Ureteroscopy in patients with coagulopathies is associated with lower stone-free rate and increased risk of clinically significant hematuria. *Int Braz J Urol.* 2012;38(2):195-202. doi:10.1590/S1677-55382012000200007

172. Kumar V, Ahlawat R, Banjeree GK, Bhaduria RP, Elhence A, Bhandari M. Percutaneous ureterolitholapaxy: the best bet to clear large bulk impacted upper ureteral calculi. *Arch Esp Urol.* 1996;49(1):86-91.

173. Rhee BK, Bretan Jr PN, Stoller ML. Urolithiasis in renal and combined pancreas/renal transplant recipients. *J Urol*. 1999;161(5):1458-1462.
174. Okhunov Z, Duty B, Smith AD, Okeke Z. Management of urolithiasis in patients after urinary diversions. *BJU Int*. 2011;108(3):330-336. doi:10.1111/j.1464-410X.2011.10194.x
175. Fernandez A, Foell K, Nott L, Denstedt JD, Razvi H. Percutaneous nephrolithotripsy in patients with urinary diversions: A case-control comparison of perioperative outcomes. *J Endourol*. 2011;25(10):1615-1618. doi:10.1089/end.2011.0045
176. Maheshwari PN, Oswal AT, Andankar M, Nanjappa KM, Bansal M. Is antegrade ureteroscopy better than retrograde ureteroscopy for impacted large upper ureteral calculi? *J Endourol*. 1999;13(6):441-444. doi:10.1089/end.1999.13.441
177. Goel R, Aron M, Kesarwani PK, Dogra PN, Hemal AK, Gupta NP. Percutaneous antegrade removal of impacted upper-ureteral calculi: Still the treatment of choice in developing countries. *J Endourol*. 2005;19(1):54-57. doi:10.1089/end.2005.19.54
178. Karami H, Arbab AHMM, Hosseini SJ, Razzaghi MR, Simaei NR. Impacted upper-ureteral calculi >1 cm: Blind access and totally tubeless percutaneous antegrade removal or retrograde approach? *J Endourol*. 2006;20(9):616-619. doi:10.1089/end.2006.20.616
179. Topaloglu H, Karakoyunlu N, Sari S, Ozok HU, Sagnak L, Ersoy H. A Comparison of Antegrade Percutaneous and Laparoscopic Approaches in the Treatment of Proximal Ureteral Stones. *Biomed Res Int*. 2014;2014. doi:10.1155/2014/691946
180. Zhu H, Ye X, Xiao X, Chen X, Zhang Q, Wang H. Retrograde, antegrade, and laparoscopic approaches to the management of large upper ureteral stones after shockwave lithotripsy failure: A four-year retrospective study. *J Endourol*. 2014;28(1):100-103. doi:10.1089/end.2013.0391
181. Sfoungaristos S, Mykoniatis I, Isid A, et al. Retrograde versus Antegrade Approach for the Management of Large Proximal Ureteral Stones. *Biomed Res Int*. 2016;2016. doi:10.1155/2016/6521461
182. Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD. Temporal trends in incidence of kidney stones among children: A 25-year population based study. *J Urol*. 2012;188(1):247-252. doi:10.1016/j.juro.2012.03.021
183. Routh JC, Graham DA, Nelson CP. Epidemiological trends in pediatric urolithiasis at United States freestanding pediatric hospitals. *J Urol*. 2010;184(3):1100-1105. doi:10.1016/j.juro.2010.05.018
184. Ellison JS, Yonekawa K. Recent Advances in the Evaluation, Medical, and Surgical Management of Pediatric Nephrolithiasis. *Curr Pediatr Rep*. 2018;6(3):198-208. doi:10.1007/s40124-018-0176-5
185. Radmayr C, Bogaert G, Dogan HS, et al. *EAU Guidelines on Pediatric Urology*. Barcelona; 2019.
186. Fulgham PF, Assimos DG, Pearle MS, Preminger GM. Clinical effectiveness protocols for imaging in the management of ureteral calculous disease: AUA technology assessment. *J Urol*. 2013;189(4):1203-1213. doi:10.1016/j.juro.2012.10.031
187. Rob S, Jones P, Pietropaolo A, Griffin S, Somani BK. Ureteroscopy for Stone Disease in Paediatric Population is Safe and Effective in Medium-Volume and High-Volume Centres: Evidence from a Systematic Review. *Curr Urol Rep*. 2017;18(12). doi:10.1007/s11934-017-0742-3
188. Jones P, Rob S, Griffin S, Somani BK. Outcomes of ureteroscopy (URS) for stone disease in the paediatric population: results of over 100 URS procedures from a UK tertiary centre. *World J Urol*. 2020;38(1):213-218. doi:10.1007/s00345-019-02745-3
189. Johnson EK, Graham DA, Chow JS, Nelson CP. Nationwide emergency department imaging

- practices for pediatric urolithiasis: Room for improvement. *J Urol*. 2014;192(1):200-206. doi:10.1016/j.juro.2014.01.028
190. Ziembra JB, Canning DA, Lavelle J, Kalmus A, Tasian GE. Patient and institutional characteristics associated with initial computerized tomography in children presenting to the emergency department with kidney stones. *J Urol*. 2015;193(5):1848-1854. doi:10.1016/j.juro.2014.09.115
191. Strohmaier WL. Imaging in pediatric urolithiasis-what's the best choice? *Transl Pediatr*. 2015;4(1):36-40. doi:10.3978/j.issn.2224-4336.2015.01.01
192. Niemann T, Kollmann T, Bongartz G. Diagnostic performance of low-dose CT for the detection of urolithiasis: A meta-analysis. *Am J Roentgenol*. 2008;191(2):396-401. doi:10.2214/AJR.07.3414
193. Barreto L, Jung JH, Abdelrahim A, Ahmed M, Dawkins GPC, Kazmierski M. Medical and surgical interventions for the treatment of urinary stones in children. *Cochrane Database Syst Rev*. 2018;2018(6). doi:10.1002/14651858.CD010784.pub2
194. Tasian GE, Cost NG, Granberg CF, et al. Tamsulosin and spontaneous passage of ureteral stones in children: A multi-institutional cohort study. *J Urol*. 2014;192(2):506-511. doi:10.1016/j.juro.2014.01.091
195. Pietrow PK, Pope IV JC, Adams MC, Shyr Y, Brock JW. Clinical outcome of pediatric stone disease. *J Urol*. 2002;167(2 Pt 1):670-673. doi:10.1097/00005392-200202000-00060
196. Kim SS, Kolon TF, Canter D, White M, Casale P. Pediatric Flexible Ureteroscopic Lithotripsy: The Children's Hospital of Philadelphia Experience. *J Urol*. 2008;180(6):2616-2619. doi:10.1016/j.juro.2008.08.051
197. Velázquez N, Zapata D, Wang HHS, Wiener JS, Lipkin ME, Routh JC. Medical expulsive therapy for pediatric urolithiasis: Systematic review and meta-analysis. *J Pediatr Urol*. 2015;11(6):321-327. doi:10.1016/j.jpuro.2015.04.036
198. Basiri A, Zare S, Shakhssalim N, Hosseini Moghaddam SM. Ureteral calculi in children: what is best as a minimally invasive modality? *Urol J*. 2008;5(2):67-73.
199. De Dominicis M, Matarazzo E, Capozza N, Collura G, Caione P. Retrograde ureteroscopy for distal ureteric stone removal in children. *BJU Int*. 2005;95(7):1049-1052. doi:10.1111/j.1464-410X.2005.05464.x
200. Basiri A, Zare S, Tabibi A, et al. A multicenter, randomized, controlled trial of transureteral and shock wave Lithotripsy-Which is the best minimally invasive modality to treat distal ureteral calculi in children? *J Urol*. 2010;184(3):1106-1109. doi:10.1016/j.juro.2010.05.021
201. Esmat M, Gareeb A, Hassan AT, Abdelsami WF. *Flexible Ureteroscopy with Laser Lithotripsy versus Extracorporeal Shock Wave Lithotripsy in Management of Ureteric Stones in Pediatric Age Group*. Vol 72.; 2018.
202. Adam A. A Simple and Novel Method to Attain Retrograde Ureteral Access after Previous Cohen Cross-Trigonal Ureteral Reimplantation. *Curr Urol*. 2017;11(1):42-47. doi:10.1159/000447193
203. Ishii H, Griffin S, Somani BK. Ureteroscopy for stone disease in the paediatric population: A systematic review. *BJU Int*. 2015;115(6):867-873. doi:10.1111/bju.12927
204. Marchetti KA, Lee T, Raja N, et al. Extracorporeal shock wave lithotripsy versus ureteroscopy for management of pediatric nephrolithiasis in upper urinary tract stones: multi-institutional outcomes of efficacy and morbidity. *J Pediatr Urol*. 2019;15(5):516.e1-516.e8. doi:10.1016/j.jpuro.2019.06.006
205. Dogan HS, Onal B, Satar N, et al. Factors affecting complication rates of ureteroscopic

- lithotripsy in children: Results of multi-institutional retrospective analysis by pediatric stone disease study group of Turkish pediatric urology society. *J Urol*. 2011;186(3):1035-1040. doi:10.1016/j.juro.2011.04.097
206. Elgammal MA, Safwat AS, Elderwy A, El-Azab AS, Abdelkader MS, Hammouda HM. Primary versus secondary ureteroscopy for pediatric ureteral stones. *J Pediatr Urol*. 2014;10(6):1193-1198. doi:10.1016/j.jpuro.2014.05.010
207. Minevich E, DeFoor W, Reddy P, et al. Ureteroscopy is safe and effective in prepubertal children. *J Urol*. 2005;174(1):276-279. doi:10.1097/01.ju.0000161212.69078.e6
208. Featherstone NC, Somani BK, Griffin SJ. Ureteroscopy and laser stone fragmentation (URSL) for large ( $\geq 1$  cm) paediatric stones: Outcomes from a university teaching hospital. *J Pediatr Urol*. 2017;13(2):202.e1-202.e7. doi:10.1016/j.jpuro.2016.07.006
209. Sarica K, Erturhan S, Yurtseven C, Yağci F. Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. *J Endourol*. 2006;20(11):875-879. doi:10.1089/end.2006.20.875
210. Tasian GE, Kabarriti AE, Kalmus A, Furth SL. Kidney Stone Recurrence among Children and Adolescents. *J Urol*. 2017;197(1):246-252. doi:10.1016/j.juro.2016.07.090
211. Mullins JK, Semins MJ, Hyams ES, Bohlman ME, Matlaga BR. Half fourier single-shot turbo spin-echo magnetic resonance urography for the evaluation of suspected renal colic in pregnancy. *Urology*. 2012;79(6):1252-1255. doi:10.1016/j.urology.2011.12.016
212. Bjazevic J, Razvi H. Stones in pregnancy and pediatrics. *Asian J Urol*. 2018;5(4):223-234. doi:10.1016/j.ajur.2018.05.006
213. Regan F, Kuszyk B, Bohlman ME, Jackman S. Acute ureteric calculus obstruction: Unenhanced spiral CT versus HASTE MR urography and abdominal radiograph. *Br J Radiol*. 2005;78(930):506-511. doi:10.1259/bjr/22314006
214. White WM, Johnson EB, Zite NB, et al. Predictive value of current imaging modalities for the detection of urolithiasis during pregnancy: A multicenter, longitudinal study. *J Urol*. 2013;189(3):931-934. doi:10.1016/j.juro.2012.09.076
215. Masselli G, Derme M, Laghi F, et al. Imaging of stone disease in pregnancy. *Abdom Imaging*. 2013;38(6):1409-1414. doi:10.1007/s00261-013-0019-3
216. Semins MJ, Matlaga BR. Management of stone disease in pregnancy. *Curr Opin Urol*. 2010;20(2):174-177. doi:10.1097/MOU.0b013e3283353a4b
217. Burdan F, Starosławska E, Szumiło J. Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclooxygenase inhibitors. *Pharmacol Reports*. 2012;64(3):521-527. doi:10.1016/S1734-1140(12)70847-2
218. Bailey G, Vaughan L, Rose C, Krambeck A. Perinatal Outcomes with Tamsulosin Therapy for Symptomatic Urolithiasis. *J Urol*. 2016;195(1):99-103. doi:10.1016/j.juro.2015.06.097
219. Theriault B, Morin F, Cloutier J. Safety and efficacy of Tamsulosin as medical expulsive therapy in pregnancy. *World J Urol*. 2020;38(9):2301-2306. doi:10.1007/s00345-019-03022-z
220. Semins MJ, Matlaga BR. Kidney stones during pregnancy. *Nat Rev Urol*. 2014;11(3):163-168. doi:10.1038/nrur.2014.17
221. White J, Ory J, Lantz Powers AG, Ordon M, Kroft J, Cox A. Urological issues in pregnancy: A review for urologists. *Can Urol Assoc J*. 2020;14(10):352-357. doi:10.5489/CUAJ.6526
222. Khoo L, Anson K, Patel U. Success and short-term complication rates of percutaneous nephrostomy during pregnancy. *J Vasc Interv Radiol*. 2004;15(12):1469-1473. doi:10.1097/01.RVI.0000140639.57131.6D
223. Epelboym Y, Tivnan P, Desai K, O'Horo S. Percutaneous nephrostomy placement in

- pregnant patients: a retrospective single center experience. *J Matern Neonatal Med.* 2020. doi:10.1080/14767058.2020.1740673
224. Thomas A, Cloutier J, Villa L, Letendre J, Ploumidis A, Traxer O. Prospective Analysis of a Complete Retrograde Ureteroscopic Technique with Holmium Laser Stent Cutting for Management of Encrusted Ureteral Stents. *J Endourol.* 2017;31(5):476-481. doi:10.1089/end.2016.0816
225. Denstedt JD, Razvi H. Management of urinary calculi during pregnancy. *J Urol.* 1992;148(3 II):1072-1074. doi:10.1016/s0022-5347(17)36821-0
226. Akpınar H, Tüfek I, Alici B, Kural AR. Ureteroscopy and holmium laser lithotripsy in pregnancy: Stents must be used postoperatively. *J Endourol.* 2006;20(2):107-110. doi:10.1089/end.2006.20.107
227. Isen K, Hatipoglu NK, Dedeoglu S, Atilgan I, Çaça FN, Hatipoglu N. Experience with the diagnosis and management of symptomatic ureteric stones during pregnancy. *Urology.* 2012;79(3):508-512. doi:10.1016/j.urology.2011.10.023
228. Buttice S, Laganà AS, Vitale SG, et al. Ureteroscopy in pregnant women with complicated colic pain: Is there any risk of premature labor? *Arch Ital di Urol e Androl.* 2017;89(4):287-292. doi:10.4081/aiua.2017.4.287
229. Watterson JD, Girvan AR, Beiko DT, et al. Ureteroscopy and holmium:YAG laser lithotripsy: An emerging definitive management strategy for symptomatic ureteral calculi in pregnancy. *Urology.* 2002;60(3):383-387. doi:10.1016/S0090-4295(02)01751-X
230. Bozkurt Y, Penbegul N, Soylemez H, et al. The efficacy and safety of ureteroscopy for ureteral calculi in pregnancy: Our experience in 32 patients. *Urol Res.* 2012;40(5):531-535. doi:10.1007/s00240-011-0454-y
231. Wang Z, Xu L, Su Z, Yao C, Chen Z. Invasive management of proximal ureteral calculi during pregnancy. *Urology.* 2014;83(4):745-749. doi:10.1016/j.urology.2013.11.031
232. Gerogescu D, Multescu R, Geavlete B, Chiuu L. Ureteroscopy -- first-line treatment alternative in ureteral calculi during pregnancy? *Chir.* 2014;109(2):229-232.
233. Tan ST, Chen X, Sun M, Wu B. The comparison of effects and security of double-J stent retention and ureteroscopy lithotripsy in the treatment of symptomatic ureteral calculi during pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 2018;227:32-34. doi:10.1016/j.ejogrb.2018.05.041
234. Semins MJ, Trock BJ, Matlaga BR. The Safety of Ureteroscopy During Pregnancy: A Systematic Review and Meta-Analysis. *J Urol.* 2009;181(1):139-143. doi:10.1016/j.juro.2008.09.029
235. Cheek TG, Baird E. Anesthesia for nonobstetric surgery: Maternal and fetal considerations. *Clin Obstet Gynecol.* 2009;52(4):535-545. doi:10.1097/GRF.0b013e3181c11f60
236. Cocuzza M, Colombo JR, Lopes RI, Piovesan AC, Borges Mesquita JL, Srougi M. Use of Inverted Fluoroscope's C-arm During Endoscopic Treatment of Urinary Tract Obstruction in Pregnancy: A Practicable Solution to Cut Radiation. *Urology.* 2010;75(6):1505-1508. doi:10.1016/j.urology.2009.12.014
237. Frankenschmidt A, Sommerkamp H. Shock wave lithotripsy during pregnancy: A successful clinical experiment. *J Urol.* 1998;159(2):501-502. doi:10.1016/S0022-5347(01)63962-4
238. Shah A, Chandak P, Tiptaft R, Glass J, Dasgupta P. Percutaneous nephrolithotomy in early pregnancy. *Int J Clin Pract.* 2004;58(8):809-810. doi:10.1111/j.1368-5031.2004.00047.x